0000050863 December 28 2025 Q2 FALSE xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 0000050863 2024-12-29 2025-06-28 0000050863 2025-07-18 0000050863 2025-03-30 2025-06-28 0000050863 2024-03-31 2024-06-29 0000050863 2023-12-31 2024-06-29 0000050863 2025-06-28 0000050863 2024-12-28 0000050863 2023-12-30 0000050863 2024-06-29 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-03-29 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-29 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2025-03-29 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:NoncontrollingInterestMember 2025-03-29 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2025-03-29 0000050863 us-gaap:RetainedEarningsMember 2025-03-30 2025-06-28 0000050863 us-gaap:NoncontrollingInterestMember 2025-03-30 2025-06-28 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 2025-06-28 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-03-30 2025-06-28 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2025-06-28 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-28 0000050863 us-gaap:RetainedEarningsMember 2025-06-28 0000050863 us-gaap:NoncontrollingInterestMember 2025-06-28 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-30 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 0000050863 us-gaap:RetainedEarningsMember 2024-03-30 0000050863 us-gaap:NoncontrollingInterestMember 2024-03-30 0000050863 2024-03-30 0000050863 us-gaap:RetainedEarningsMember 2024-03-31 2024-06-29 0000050863 us-gaap:NoncontrollingInterestMember 2024-03-31 2024-06-29 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 2024-06-29 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-31 2024-06-29 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-06-29 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-29 0000050863 us-gaap:RetainedEarningsMember 2024-06-29 0000050863 us-gaap:NoncontrollingInterestMember 2024-06-29 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-12-28 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-28 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2024-12-28 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:NoncontrollingInterestMember 2024-12-28 0000050863 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2024-12-28 0000050863 us-gaap:RetainedEarningsMember 2024-12-29 2025-06-28 0000050863 us-gaap:NoncontrollingInterestMember 2024-12-29 2025-06-28 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 2025-06-28 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-12-29 2025-06-28 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-30 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-30 0000050863 us-gaap:RetainedEarningsMember 2023-12-30 0000050863 us-gaap:NoncontrollingInterestMember 2023-12-30 0000050863 us-gaap:RetainedEarningsMember 2023-12-31 2024-06-29 0000050863 us-gaap:NoncontrollingInterestMember 2023-12-31 2024-06-29 0000050863 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 2024-06-29 0000050863 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:AssemblyAndTestMember intc:IntelFoundryMember 2025-03-30 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:AssemblyAndTestMember intc:IntelFoundryMember 2024-12-29 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:AssemblyAndTestMember intc:IntelFoundryMember 2024-03-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:AssemblyAndTestMember intc:IntelFoundryMember 2023-12-31 2024-06-29 0000050863 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember intc:AlteraMember srt:ScenarioForecastMember 2025-12-27 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupMember 2025-03-30 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:DatacenterAndAIMember 2025-03-30 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupDatacenterAndAIAndNetworkAndEdgeMember 2025-03-30 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:IntelFoundryMember 2025-03-30 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2025-03-30 2025-06-28 0000050863 us-gaap:IntersegmentEliminationMember 2025-03-30 2025-06-28 0000050863 us-gaap:CorporateNonSegmentMember 2025-03-30 2025-06-28 0000050863 intc:ClientComputingGroupMember 2025-03-30 2025-06-28 0000050863 intc:DatacenterAndAIMember 2025-03-30 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupMember 2024-03-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:DatacenterAndAIMember 2024-03-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupDatacenterAndAIAndNetworkAndEdgeMember 2024-03-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:IntelFoundryMember 2024-03-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2024-03-31 2024-06-29 0000050863 us-gaap:IntersegmentEliminationMember 2024-03-31 2024-06-29 0000050863 us-gaap:CorporateNonSegmentMember 2024-03-31 2024-06-29 0000050863 intc:ClientComputingGroupMember 2024-03-31 2024-06-29 0000050863 intc:DatacenterAndAIMember 2024-03-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupMember 2024-12-29 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:DatacenterAndAIMember 2024-12-29 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupDatacenterAndAIAndNetworkAndEdgeMember 2024-12-29 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:IntelFoundryMember 2024-12-29 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2024-12-29 2025-06-28 0000050863 us-gaap:IntersegmentEliminationMember 2024-12-29 2025-06-28 0000050863 us-gaap:CorporateNonSegmentMember 2024-12-29 2025-06-28 0000050863 intc:ClientComputingGroupMember 2024-12-29 2025-06-28 0000050863 intc:DatacenterAndAIMember 2024-12-29 2025-06-28 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupMember 2023-12-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:DatacenterAndAIMember 2023-12-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:ClientComputingGroupDatacenterAndAIAndNetworkAndEdgeMember 2023-12-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember intc:IntelFoundryMember 2023-12-31 2024-06-29 0000050863 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2023-12-31 2024-06-29 0000050863 us-gaap:IntersegmentEliminationMember 2023-12-31 2024-06-29 0000050863 us-gaap:CorporateNonSegmentMember 2023-12-31 2024-06-29 0000050863 intc:ClientComputingGroupMember 2023-12-31 2024-06-29 0000050863 intc:DatacenterAndAIMember 2023-12-31 2024-06-29 0000050863 intc:IrelandSCIPMember 2025-06-28 0000050863 intc:IrelandSCIPMember 2024-06-29 0000050863 intc:ArizonaSCIPMember 2025-06-28 0000050863 intc:ArizonaSCIPMember 2024-06-29 0000050863 intc:MobileyeMember 2025-06-28 0000050863 intc:MobileyeMember 2024-06-29 0000050863 intc:IMSNanofabricationGmbHIMSMember 2025-06-28 0000050863 intc:IMSNanofabricationGmbHIMSMember 2024-06-29 0000050863 intc:SubsidiariesIrelandSCIPMember 2024-12-28 0000050863 intc:SubsidiariesArizonaSCIPMember 2024-12-28 0000050863 intc:SubsidiariesMobileyeMember 2024-12-28 0000050863 intc:SubsidiariesIMSNanofabricationGmbHIMSMember 2024-12-28 0000050863 intc:SubsidiariesIrelandSCIPMember 2024-12-29 2025-06-28 0000050863 intc:SubsidiariesArizonaSCIPMember 2024-12-29 2025-06-28 0000050863 intc:SubsidiariesMobileyeMember 2024-12-29 2025-06-28 0000050863 intc:SubsidiariesIMSNanofabricationGmbHIMSMember 2024-12-29 2025-06-28 0000050863 intc:SubsidiariesIrelandSCIPMember 2025-06-28 0000050863 intc:SubsidiariesArizonaSCIPMember 2025-06-28 0000050863 intc:SubsidiariesMobileyeMember 2025-06-28 0000050863 intc:SubsidiariesIMSNanofabricationGmbHIMSMember 2025-06-28 0000050863 intc:SubsidiariesIrelandSCIPMember 2023-12-30 0000050863 intc:SubsidiariesArizonaSCIPMember 2023-12-30 0000050863 intc:SubsidiariesMobileyeMember 2023-12-30 0000050863 intc:SubsidiariesIMSNanofabricationGmbHIMSMember 2023-12-30 0000050863 intc:SubsidiariesIrelandSCIPMember 2023-12-31 2024-06-29 0000050863 intc:SubsidiariesArizonaSCIPMember 2023-12-31 2024-06-29 0000050863 intc:SubsidiariesMobileyeMember 2023-12-31 2024-06-29 0000050863 intc:SubsidiariesIMSNanofabricationGmbHIMSMember 2023-12-31 2024-06-29 0000050863 intc:SubsidiariesIrelandSCIPMember 2024-06-29 0000050863 intc:SubsidiariesArizonaSCIPMember 2024-06-29 0000050863 intc:SubsidiariesMobileyeMember 2024-06-29 0000050863 intc:SubsidiariesIMSNanofabricationGmbHIMSMember 2024-06-29 0000050863 intc:VariableInterestEntityPrimaryBeneficiaryIrelandSCIPMember 2024-12-29 2025-06-28 0000050863 intc:VariableInterestEntityPrimaryBeneficiaryIrelandSCIPMember 2025-06-28 0000050863 us-gaap:AssetPledgedAsCollateralMember intc:VariableInterestEntityPrimaryBeneficiaryArizonaSCIPMember 2025-06-28 0000050863 us-gaap:AssetPledgedAsCollateralMember intc:VariableInterestEntityPrimaryBeneficiaryArizonaSCIPMember 2024-12-28 0000050863 intc:SubsidiariesMobileyeMember us-gaap:SubsequentEventMember 2025-07-11 2025-07-11 0000050863 intc:SubsidiariesMobileyeMember us-gaap:SubsequentEventMember 2025-07-11 0000050863 intc:SubsidiariesMobileyeMember intc:MobileyeMember us-gaap:SubsequentEventMember 2025-07-11 2025-07-11 0000050863 intc:ValueOfManufacturingAssetPortfolioMember 2025-03-30 2025-06-28 0000050863 intc:A2025RestructuringPlanMember 2025-03-30 2025-06-28 0000050863 intc:NANDMemoryBusinessMember 2025-03-30 2025-06-28 0000050863 intc:CapitalRelatedGrantAndOperatingGrantFederalMember 2024-12-29 2025-06-28 0000050863 intc:CapitalRelatedGrantFederalMember 2024-12-29 2025-06-28 0000050863 intc:OperatingGrantFederalMember 2024-12-29 2025-06-28 0000050863 intc:OperatingGrantFederalMember 2025-03-30 2025-06-28 0000050863 intc:RefundableAdvancedManufacturingInvestmentTaxCreditMember 2024-12-29 2025-06-28 0000050863 intc:RefundableAdvancedManufacturingInvestmentTaxCreditMember 2023-12-31 2024-06-29 0000050863 intc:A2025RestructuringPlanMember 2025-06-28 0000050863 intc:A2024RestructuringPlanMember 2025-06-28 0000050863 intc:A2025RestructuringPlanMember 2024-12-28 0000050863 intc:A2024RestructuringPlanMember 2024-12-28 0000050863 intc:A2025RestructuringPlanMember 2024-12-29 2025-06-28 0000050863 intc:A2024RestructuringPlanMember 2024-12-29 2025-06-28 0000050863 intc:SemiconductorPatentLitigationMember 2024-03-31 2024-06-29 0000050863 us-gaap:AvailableforsaleSecuritiesMember 2025-06-28 0000050863 us-gaap:AvailableforsaleSecuritiesMember 2024-12-28 0000050863 intc:SingleInvesteeMember 2025-03-30 2025-06-28 0000050863 intc:NANDMemoryBusinessMember 2025-03-27 2025-03-27 0000050863 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember intc:AlteraMember srt:ScenarioForecastMember 2025-06-29 2027-12-31 0000050863 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember intc:AlteraMember srt:ScenarioForecastMember 2026-12-31 2027-12-31 0000050863 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember intc:AlteraMember srt:ScenarioForecastMember 2026-12-31 2026-12-31 0000050863 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember intc:AlteraMember srt:ScenarioForecastMember 2027-12-31 2027-12-31 0000050863 intc:AlteraMember srt:ScenarioForecastMember 2025-12-27 0000050863 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember intc:AlteraMember 2025-04-14 0000050863 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember intc:AlteraMember 2025-06-28 0000050863 intc:CreditFacility364DayMember us-gaap:LineOfCreditMember 2024-12-29 2025-06-28 0000050863 intc:CreditFacility364DayMember us-gaap:LineOfCreditMember 2024-12-28 0000050863 intc:CreditFacility364DayMember us-gaap:LineOfCreditMember 2025-06-28 0000050863 us-gaap:CommercialPaperMember 2025-06-28 0000050863 us-gaap:CommercialPaperMember srt:MinimumMember 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:FixedIncomeSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 intc:GovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-06-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-06-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-12-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-12-28 0000050863 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-28 0000050863 us-gaap:FairValueMeasurementsNonrecurringMember 2025-06-28 0000050863 us-gaap:FairValueMeasurementsNonrecurringMember 2024-12-28 0000050863 us-gaap:FairValueInputsLevel2Member 2025-06-28 0000050863 us-gaap:FairValueInputsLevel2Member 2024-12-28 0000050863 us-gaap:ForeignExchangeContractMember 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember 2024-12-28 0000050863 us-gaap:InterestRateContractMember 2025-06-28 0000050863 us-gaap:InterestRateContractMember 2024-12-28 0000050863 us-gaap:OtherContractMember 2025-06-28 0000050863 us-gaap:OtherContractMember 2024-12-28 0000050863 us-gaap:InterestRateSwapMember us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000050863 us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-28 0000050863 us-gaap:OtherLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-28 0000050863 us-gaap:OtherAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000050863 us-gaap:OtherLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:InterestRateContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:EquityContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:EquityContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:EquityContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:EquityContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:OtherContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:OtherContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:OtherContractMember us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:OtherContractMember us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2025-06-28 0000050863 us-gaap:OtherAssetsMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:OtherLiabilitiesMember us-gaap:NondesignatedMember 2024-12-28 0000050863 us-gaap:OtherAssetsMember 2025-06-28 0000050863 us-gaap:OtherLiabilitiesMember 2025-06-28 0000050863 us-gaap:OtherAssetsMember 2024-12-28 0000050863 us-gaap:OtherLiabilitiesMember 2024-12-28 0000050863 us-gaap:ForeignExchangeContractMember 2025-03-30 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember 2024-12-29 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember 2024-03-31 2024-06-29 0000050863 us-gaap:ForeignExchangeContractMember 2023-12-31 2024-06-29 0000050863 us-gaap:FairValueHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-12-29 2025-06-28 0000050863 us-gaap:InterestRateContractMember 2025-03-30 2025-06-28 0000050863 us-gaap:InterestRateContractMember 2024-03-31 2024-06-29 0000050863 us-gaap:InterestRateContractMember 2024-12-29 2025-06-28 0000050863 us-gaap:InterestRateContractMember 2023-12-31 2024-06-29 0000050863 us-gaap:InterestRateSwapMember us-gaap:ShortTermDebtMember 2025-06-28 0000050863 us-gaap:InterestRateSwapMember us-gaap:ShortTermDebtMember 2024-12-28 0000050863 us-gaap:InterestRateSwapMember us-gaap:LongTermDebtMember 2025-06-28 0000050863 us-gaap:InterestRateSwapMember us-gaap:LongTermDebtMember 2024-12-28 0000050863 us-gaap:InterestRateSwapMember 2025-06-28 0000050863 us-gaap:InterestRateSwapMember 2024-12-28 0000050863 us-gaap:NondesignatedMember 2024-12-29 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-03-30 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-03-31 2024-06-29 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-29 2025-06-28 0000050863 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 2024-06-29 0000050863 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2025-03-30 2025-06-28 0000050863 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2024-03-31 2024-06-29 0000050863 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2024-12-29 2025-06-28 0000050863 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2023-12-31 2024-06-29 0000050863 us-gaap:OtherContractMember us-gaap:NondesignatedMember 2025-03-30 2025-06-28 0000050863 us-gaap:OtherContractMember us-gaap:NondesignatedMember 2024-03-31 2024-06-29 0000050863 us-gaap:OtherContractMember us-gaap:NondesignatedMember 2024-12-29 2025-06-28 0000050863 us-gaap:OtherContractMember us-gaap:NondesignatedMember 2023-12-31 2024-06-29 0000050863 us-gaap:NondesignatedMember 2025-03-30 2025-06-28 0000050863 us-gaap:NondesignatedMember 2024-03-31 2024-06-29 0000050863 us-gaap:NondesignatedMember 2023-12-31 2024-06-29 0000050863 intc:EcFineMember 2025-06-28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|  | For the quarterly period ended | June 28, 2025

or

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|  | For the transition period from to

Commission File Number: 000-06217
INTEL CORPORATION
(Exact name of registrant as specified in its charter)

| Delaware |  |  | 94-1672743
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
2200 Mission College Boulevard, | Santa Clara, | California |  | 95054-1549
(Address of principal executive offices) |  | (Zip Code)

(408) 765-8080
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common stock, $0.001 par value | INTC | Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | Accelerated filer |  | Non-accelerated filer |  | Smaller reporting company | Emerging growth company
☑ |  | ¨ |  | ¨ |  | ☐ | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
As of July 18, 2025, the registrant had outstanding 4,377 million shares of common stock.

Table of Contents
Organization of Our Form 10-Q
The order and presentation of content in our Form 10-Q differs from the traditional SEC Form 10-Q format. Our format is designed to improve readability and better present how we organize and manage our business. See "Form 10-Q Cross-Reference Index" within Risk Factors and Other Key Information for a cross-reference index to the traditional SEC Form 10-Q format.
We have defined certain terms and abbreviations used throughout our Form 10-Q in "Key Terms" within the Consolidated Condensed Financial Statements and Supplemental Details.

|  |  | Page
Forward-Looking Statements | 1
Availability of Company Information | 2
Consolidated Condensed Financial Statements and Supplemental Details |
| Consolidated Condensed Statements of Operations | 3
| Consolidated Condensed Statements of Comprehensive Income (Loss) | 4
| Consolidated Condensed Balance Sheets | 5
| Consolidated Condensed Statements of Cash Flows | 6
| Consolidated Condensed Statements of Stockholders' Equity | 7
| Notes to Consolidated Condensed Financial Statements | 8
| Key Terms | 25
Management's Discussion and Analysis (MD&A) |
| Operating Segments Trends and Results | 27
| Consolidated Condensed Results of Operations | 31
| Liquidity and Capital Resources | 37
| Critical Accounting Estimates | 38
Risk Factors and Other Key Information |
| Risk Factors | 41
| Quantitative and Qualitative Disclosures About Market Risk | 42
| Controls and Procedures | 42
| Issuer Purchases of Equity Securities | 43
| Rule 10b5-1 Trading Arrangements | 43
| Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934 | 43
| Amendment and Restatement of the 2006 Equity Incentive Plan | 43
| Exhibits | 44
| Form 10-Q Cross-Reference Index | 45

Table of Contents
Forward-Looking Statements
This Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Words such as "accelerate", "achieve", "aim", "ambitions", "anticipate", "believe", "committed", "continue", "could", "designed", "estimate", "expect", "forecast", "future", "goals", "grow", "guidance", "intend", "likely", "may", "might", "milestones", "next generation", "objective", "on track", "opportunity", "outlook", "pending", "plan", "position", "possible", "potential", "predict", "progress", "ramp", "roadmap", "seek", "should", "strive", "targets", "to be", "upcoming", "will", "would", and variations of such words and similar expressions are intended to identify such forward-looking statements, which may include statements regarding:
▪our business plans and strategy and anticipated benefits therefrom, including with respect to our intentions and expectations for Intel 14A, our IDM strategy, our Smart Capital strategy, our partnerships with Apollo and Brookfield, our internal foundry model, our updated reporting structure, and our AI strategy;
▪projections of our future financial performance, including future revenue, gross profits, capital expenditures, and cash flows;
▪projected costs and yield trends;
▪future cash requirements, the availability, uses, sufficiency, and cost of capital resources, and sources of funding, including for future capital and R&D investments and for returns to stockholders, such as stock repurchases and dividends, and credit ratings expectations;
▪future products, services, and technologies, and the expected goals, timeline, ramps, progress, availability, production, regulation, and benefits of such products, services, and technologies, including future process nodes and packaging technology, product roadmaps, schedules, future product architectures, expectations regarding process performance, per-watt parity, and metrics, and expectations regarding product and process leadership;
▪investment plans and impacts of investment plans, including in the US and abroad;
▪internal and external manufacturing plans, including future internal manufacturing volumes, manufacturing expansion plans and the financing therefor, and external foundry usage;
▪future production capacity and product supply;
▪supply expectations, including regarding constraints, limitations, pricing, and industry shortages;
▪plans and goals related to Intel's foundry business, including with respect to anticipated customers, future manufacturing capacity and service, technology, and IP offerings;
▪expected timing and impact of acquisitions, divestitures, and other significant transactions, including the agreed-upon sale of a controlling interest of Altera;
▪expected completion and impacts of restructuring activities and cost-saving or efficiency initiatives;
▪future social and environmental performance goals, measures, strategies, and results;
▪our anticipated growth, future market share, customer demand, and trends in our businesses and operations;
▪projected growth and trends in markets relevant to our businesses;
▪anticipated trends and impacts related to industry component, substrate, and foundry capacity utilization, shortages, and constraints;
▪expectations regarding government incentives, policies, and priorities;
▪future technology trends and developments, such as AI;
▪future macro environmental and economic conditions;
▪geopolitical tensions and conflicts, including with respect to international trade policies in areas such as tariffs and export controls, and their potential impact on our business;
▪tax- and accounting-related expectations;
▪expectations regarding our relationships with certain sanctioned parties; and
▪other characterizations of future events or circumstances.
Such statements involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied, including those associated with:
▪the high level of competition and rapid technological change in our industry;
▪the significant long-term and inherently risky investments we are making in R&D and manufacturing facilities that may not realize a favorable return;
▪the complexities and uncertainties in developing and implementing new semiconductor products and manufacturing process technologies;
▪our ability to time and scale our capital investments appropriately and successfully secure favorable alternative financing arrangements and government grants;
▪a potential pause or discontinuation of our pursuit of Intel 14A and other next generation leading-edge process technologies if we are unable to secure a significant external customer for Intel 14A;
▪implementing new business strategies and investing in new businesses and technologies;
▪changes in demand for our products;

|  | 1

Table of Contents
▪macroeconomic conditions and geopolitical tensions and conflicts, including geopolitical and trade tensions between the US and China, the impacts of Russia's war on Ukraine, tensions and conflict affecting Israel and the Middle East, and rising tensions between mainland China and Taiwan;
▪the evolving market for products with AI capabilities;
▪our complex global supply chain supporting our manufacturing facilities and incorporating external foundries, including from disruptions, delays, trade tensions and conflicts, or shortages;
▪recently elevated geopolitical tensions, volatility and uncertainty with respect to international trade policies, including tariffs and export controls, impacting our business, the markets in which we compete and the world economy;
▪product defects, errata and other product issues, particularly as we develop next-generation products and implement next-generation manufacturing process technologies;
▪potential security vulnerabilities in our products;
▪increasing and evolving cybersecurity threats and privacy risks;
▪IP risks including related litigation and regulatory proceedings;
▪the need to attract, retain, and motivate key talent;
▪strategic transactions and investments;
▪sales-related risks, including customer concentration and the use of distributors and other third parties;
▪our significantly reduced return of capital in recent years;
▪our debt obligations and our ability to access sources of capital;
▪complex and evolving laws and regulations across many jurisdictions;
▪fluctuations in currency exchange rates;
▪changes in our effective tax rate and applicable tax regimes;
▪catastrophic events;
▪environmental, health, safety, and product regulations;
▪our initiatives and new legal requirements with respect to corporate responsibility matters; and
▪other risks and uncertainties described in this report, our 2024 Form 10-K and our other filings with the SEC.
Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this Form 10-Q and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business.
Unless specifically indicated otherwise, the forward-looking statements in this Form 10-Q do not reflect the potential impact of any divestitures, mergers, acquisitions, or other business combinations that have not been completed as of the date of this filing. In addition, the forward-looking statements in this Form 10-Q are based on management's expectations as of the date of this filing, unless an earlier date is specified, including expectations based on third-party information and projections that management believes to be reputable. We do not undertake, and expressly disclaim any duty, to update such statements, whether as a result of new information, new developments, or otherwise, except to the extent that disclosure may be required by law.
Availability of Company Information
We use our Investor Relations website, www.intc.com, as a routine channel for distribution of important, and often material, information about us, including our quarterly and annual earnings results and presentations, press releases, announcements, information about upcoming webcasts, analyst presentations, and investor days, archives of these events, financial information, corporate governance practices, and corporate responsibility information. We also post our filings on this website the same day they are electronically filed with, or furnished to, the SEC, including our annual and quarterly reports on Forms 10-K and 10-Q and current reports on Form 8-K, our proxy statements, and any amendments to those reports. All such information is available free of charge. Our Investor Relations website allows interested persons to sign up to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events. We encourage interested persons to follow our Investor Relations website in addition to our filings with the SEC to timely receive information about the company.
Intel, the Intel logo, Intel Core, Gaudi, and Altera are trademarks of Intel Corporation or its subsidiaries in the US and/or other countries.
* Other names and brands may be claimed as the property of others.

|  | 2

Table of Contents

Consolidated Condensed Statements of Operations |

|  | Three Months Ended |  | Six Months Ended
(In Millions, Except Per Share Amounts; Unaudited) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Net revenue |  | $ | 12,859 |  |  | $ | 12,833 |  |  | $ | 25,526 |  |  | $ | 25,557 |
Cost of sales |  | 9,317 |  |  | 8,286 |  |  | 17,312 |  |  | 15,793 |
Gross profit |  | 3,542 |  |  | 4,547 |  |  | 8,214 |  |  | 9,764 |
Research and development |  | 3,684 |  |  | 4,239 |  |  | 7,324 |  |  | 8,621 |
Marketing, general, and administrative |  | 1,144 |  |  | 1,329 |  |  | 2,321 |  |  | 2,885 |
Restructuring and other charges |  | 1,890 |  |  | 943 |  |  | 2,046 |  |  | 1,291 |
Operating expenses |  | 6,718 |  |  | 6,511 |  |  | 11,691 |  |  | 12,797 |
Operating income (loss) |  | (3,176) |  |  | (1,964) |  |  | (3,477) |  |  | (3,033) |
Gains (losses) on equity investments, net |  | 502 |  |  | (120) |  |  | 390 |  |  | 85 |
Interest and other, net |  | (95) |  |  | 80 |  |  | (268) |  |  | 225 |
Income (loss) before taxes |  | (2,769) |  |  | (2,004) |  |  | (3,355) |  |  | (2,723) |
Provision for (benefit from) taxes |  | 255 |  |  | (350) |  |  | 556 |  |  | (632) |
Net income (loss) |  | (3,024) |  |  | (1,654) |  |  | (3,911) |  |  | (2,091) |
Less: net income (loss) attributable to non-controlling interests |  | (106) |  |  | (44) |  |  | (172) |  |  | (100) |
Net income (loss) attributable to Intel |  | $ | (2,918) |  |  | $ | (1,610) |  |  | $ | (3,739) |  |  | $ | (1,991) |
Earnings (loss) per share attributable to Intel—basic |  | $ | (0.67) |  |  | $ | (0.38) |  |  | $ | (0.86) |  |  | $ | (0.47) |
Earnings (loss) per share attributable to Intel—diluted |  | $ | (0.67) |  |  | $ | (0.38) |  |  | $ | (0.86) |  |  | $ | (0.47) |
Weighted average shares of common stock outstanding: |  |  |  |  |  |  |  |
Basic |  | 4,369 |  |  | 4,267 |  |  | 4,356 |  |  | 4,254 |
Diluted |  | 4,369 |  |  | 4,267 |  |  | 4,356 |  |  | 4,254 |

See accompanying notes.

| Financial Statements | Consolidated Condensed Statements of Income | 3

Table of Contents

Consolidated Condensed Statements of Comprehensive Income (Loss) |

|  | Three Months Ended |  | Six Months Ended
(In Millions; Unaudited) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Net income (loss) |  | $ | (3,024) |  |  | $ | (1,654) |  |  | $ | (3,911) |  |  | $ | (2,091) |
Changes in other comprehensive income (loss), net of tax: |  |  |  |  |  |  |  |
Net unrealized holding gains (losses) on derivatives |  | 550 |  |  | (153) |  |  | 775 |  |  | (481) |
Actuarial valuation and other pension benefits (expenses), net |  | — |  |  | — |  |  | 1 |  |  | — |
Translation adjustments and other |  | 1 |  |  | (1) |  |  | — |  |  | — |
Other comprehensive income (loss) |  | 551 |  |  | (154) |  |  | 776 |  |  | (481) |
Total comprehensive income (loss) |  | (2,473) |  |  | (1,808) |  |  | (3,135) |  |  | (2,572) |
Less: comprehensive income (loss) attributable to non-controlling interests |  | (106) |  |  | (44) |  |  | (172) |  |  | (100) |
Total comprehensive income (loss) attributable to Intel |  | $ | (2,367) |  |  | $ | (1,764) |  |  | $ | (2,963) |  |  | $ | (2,472) |

See accompanying notes.

| Financial Statements | Consolidated Condensed Statements of Comprehensive Income | 4

Table of Contents

Consolidated Condensed Balance Sheets |

(In Millions; Unaudited) |  | Jun 28, 2025 |  | Dec 28, 2024
Assets |  |  |  |
Current assets: |  |  |  |
Cash and cash equivalents |  | $ | 9,643 |  |  | $ | 8,249 |
Short-term investments |  | 11,563 |  |  | 13,813 |
Accounts receivable, net |  | 2,360 |  |  | 3,478 |
Inventories |  | 11,377 |  |  | 12,198 |
Other current assets |  | 8,432 |  |  | 9,586 |
Total current assets |  | 43,375 |  |  | 47,324 |
Property, plant, and equipment, net of accumulated depreciation of $103,572 ($102,193 as of December 28, 2024) |  | 109,510 |  |  | 107,919 |
Equity investments |  | 5,383 |  |  | 5,383 |
Goodwill |  | 23,912 |  |  | 24,693 |
Identified intangible assets, net |  | 3,057 |  |  | 3,691 |
Other long-term assets |  | 7,283 |  |  | 7,475 |
Total assets |  | $ | 192,520 |  |  | $ | 196,485 |
Liabilities and stockholders’ equity |  |  |  |
Current liabilities: |  |  |  |
Accounts payable |  | $ | 10,666 |  |  | $ | 12,556 |
Accrued compensation and benefits |  | 4,249 |  |  | 3,343 |
Short-term debt |  | 6,731 |  |  | 3,729 |
Income taxes payable |  | 887 |  |  | 1,756 |
Other accrued liabilities |  | 12,433 |  |  | 14,282 |
Total current liabilities |  | 34,966 |  |  | 35,666 |
Debt |  | 44,026 |  |  | 46,282 |
Other long-term liabilities |  | 7,777 |  |  | 9,505 |
Contingencies (Note 13) |  |  |  |
Stockholders’ equity: |  |  |  |
Common stock and capital in excess of par value, 4,377 issued and outstanding (4,330 issued and outstanding as of December 28, 2024) |  | 52,334 |  |  | 50,949 |
Accumulated other comprehensive income (loss) |  | 65 |  |  | (711) |
Retained earnings |  | 45,484 |  |  | 49,032 |
Total Intel stockholders' equity |  | 97,883 |  |  | 99,270 |
Non-controlling interests |  | 7,868 |  |  | 5,762 |
Total stockholders' equity |  | 105,751 |  |  | 105,032 |
Total liabilities and stockholders’ equity |  | $ | 192,520 |  |  | $ | 196,485 |

See accompanying notes.

| Financial Statements | Consolidated Condensed Balance Sheets | 5

Table of Contents

Consolidated Condensed Statements of Cash Flows |

|  | Six Months Ended
(In Millions; Unaudited) |  | Jun 28, 2025 |  | Jun 29, 2024
Cash and cash equivalents, beginning of period |  | $ | 8,249 |  |  | $ | 7,079 |
Cash flows provided by (used for) operating activities: |  |  |  |
Net income (loss) |  | (3,911) |  |  | (2,091) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |  |
Depreciation |  | 5,213 |  |  | 4,403 |
Share-based compensation |  | 1,348 |  |  | 1,959 |
Restructuring and other charges |  | 382 |  |  | 219 |
Amortization of intangibles |  | 474 |  |  | 717 |
(Gains) losses on equity investments, net |  | (390) |  |  | (84) |
Deferred taxes |  | 106 |  |  | (1,339) |
Impairments and net (gain) loss on retirement of property, plant, and equipment |  | 482 |  |  | 126 |
Changes in assets and liabilities: |  |  |  |
Accounts receivable |  | 1,004 |  |  | 272 |
Inventories |  | 99 |  |  | (116) |
Accounts payable |  | 114 |  |  | 181 |
Accrued compensation and benefits |  | 1,022 |  |  | (1,015) |
Income taxes |  | (1,338) |  |  | (835) |
Other assets and liabilities |  | (1,742) |  |  | (1,328) |
Total adjustments |  | 6,774 |  |  | 3,160 |
Net cash provided by (used for) operating activities |  | 2,863 |  |  | 1,069 |
Cash flows provided by (used for) investing activities: |  |  |  |
Additions to property, plant, and equipment |  | (8,733) |  |  | (11,652) |
Proceeds from capital-related government incentives |  | 964 |  |  | 699 |
Purchases of short-term investments |  | (5,730) |  |  | (17,634) |
Maturities and sales of short-term investments |  | 8,575 |  |  | 17,214 |
Proceeds from divestitures |  | 1,935 |  |  | — |
Other investing |  | 984 |  |  | (355) |
Net cash provided by (used for) investing activities |  | (2,005) |  |  | (11,728) |
Cash flows provided by (used for) financing activities: |  |  |  |
Issuance of commercial paper, net of issuance costs |  | 3,493 |  |  | 5,804 |
Repayment of commercial paper |  | (1,496) |  |  | (2,609) |
Partner contributions |  | 2,238 |  |  | 11,861 |
Additions to property, plant, and equipment |  | (1,962) |  |  | — |
Issuance of long-term debt, net of issuance costs |  | — |  |  | 2,975 |
Repayment of debt |  | (1,500) |  |  | (2,288) |
Proceeds from sales of common stock through employee equity incentive plans |  | 491 |  |  | 631 |
Payment of dividends to stockholders |  | — |  |  | (1,063) |
Other financing |  | (678) |  |  | (444) |
Net cash provided by (used for) financing activities |  | 586 |  |  | 14,867 |
Net increase (decrease) in cash and cash equivalents |  | 1,444 |  |  | 4,208 |
Cash and cash equivalents, end of period 1 |  | $ | 9,693 |  |  | $ | 11,287 |
Non-cash supplemental disclosures: |  |  |  |
Acquisition of property, plant, and equipment 2 |  | $ | 5,155 |  |  | $ | 5,544 |
Recognition of capital-related government incentives |  | $ | 1,452 |  |  | $ | 1,281 |
Cash paid during the period for: |  |  |  |
Interest, net of capitalized interest |  | $ | 514 |  |  | $ | 488 |
Income taxes, net of refunds |  | $ | 1,793 |  |  | $ | 1,555 |

1.Includes cash recorded within other current assets on the Consolidated Condensed Balance Sheets relating to Altera cash held for sale. Refer to "Note 9: Divestitures" for additional information.
2.Includes $960 million with extended payment terms of greater than 90 days in the six months ended June 28, 2025.
See accompanying notes.

| Financial Statements | Consolidated Condensed Statements of Cash Flows | 6

Table of Contents

Consolidated Condensed Statements of Stockholders' Equity |

(In Millions, Except Per Share Amounts; Unaudited) |  | Common Stock and Capital in Excess of Par Value |  | Accumulated Other Comprehensive Income (Loss) |  | Retained Earnings 1 |  | Non-Controlling Interests |  | Total
| Shares |  | Amount |  |  |  |
Three Months Ended |  |  |  |  |  |  |  |  |  |  |  |
Balance as of March 29, 2025 |  | $ | 4,362 |  |  | $ | 51,920 |  |  | $ | (486) |  |  | $ | 48,322 |  |  | $ | 6,657 |  |  | $ | 106,413 |
Net income (loss) |  | — |  |  | — |  |  | — |  |  | (2,918) |  |  | (106) |  |  | (3,024) |
Other comprehensive income (loss) |  | — |  |  | — |  |  | 551 |  |  | — |  |  | — |  |  | 551 |
Net proceeds from partner contributions |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,283 |  |  | 1,283 |
Partner distributions |  | — |  |  | — |  |  | — |  |  | — |  |  | (33) |  |  | (33) |
Employee equity incentive plans and other |  | 20 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation |  | — |  |  | 597 |  |  | — |  |  | — |  |  | 67 |  |  | 664 |
Restricted stock unit withholdings |  | (5) |  |  | (183) |  |  | — |  |  | 80 |  |  | — |  |  | (103) |
Balance as of June 28, 2025 |  | $ | 4,377 |  |  | $ | 52,334 |  |  | $ | 65 |  |  | $ | 45,484 |  |  | $ | 7,868 |  |  | $ | 105,751 |
Balance as of March 30, 2024 |  | $ | 4,257 |  |  | $ | 38,291 |  |  | $ | (542) |  |  | $ | 68,224 |  |  | $ | 4,783 |  |  | $ | 110,756 |
Net income (loss) |  | — |  |  | — |  |  | — |  |  | (1,610) |  |  | (44) |  |  | (1,654) |
Other comprehensive income (loss) |  | — |  |  | — |  |  | (154) |  |  | — |  |  | — |  |  | (154) |
Net proceeds from partner contributions |  | — |  |  | 11,012 |  |  | — |  |  | — |  |  | 426 |  |  | 11,438 |
Employee equity incentive plans and other |  | 26 |  |  | 5 |  |  | — |  |  | — |  |  | — |  |  | 5 |
Share-based compensation |  | — |  |  | 740 |  |  | — |  |  | — |  |  | 40 |  |  | 780 |
Restricted stock unit withholdings |  | (7) |  |  | (285) |  |  | — |  |  | 82 |  |  | — |  |  | (203) |
Cash dividends declared ($0.13 per share of common stock) |  | — |  |  | — |  |  | — |  |  | (534) |  |  | — |  |  | (534) |
Balance as of June 29, 2024 |  | $ | 4,276 |  |  | $ | 49,763 |  |  | $ | (696) |  |  | $ | 66,162 |  |  | $ | 5,205 |  |  | $ | 120,434 |
Six Months Ended |  |  |  |  |  |  |  |  |  |  |  |
Balance as of December 28, 2024 |  | $ | 4,330 |  |  | $ | 50,949 |  |  | $ | (711) |  |  | $ | 49,081 |  |  | $ | 5,762 |  |  | $ | 105,081 |
Net income (loss) |  | — |  |  | — |  |  | — |  |  | (3,739) |  |  | (172) |  |  | (3,911) |
Other comprehensive income (loss) |  | — |  |  | — |  |  | 776 |  |  | — |  |  | — |  |  | 776 |
Net proceeds from partner contributions |  | — |  |  | (2) |  |  | — |  |  | — |  |  | 2,240 |  |  | 2,238 |
Partner distributions |  | — |  |  | — |  |  | — |  |  | — |  |  | (91) |  |  | (91) |
Employee equity incentive plans and other |  | 56 |  |  | 491 |  |  | — |  |  | — |  |  | — |  |  | 491 |
Share-based compensation |  | — |  |  | 1,219 |  |  | — |  |  | — |  |  | 129 |  |  | 1,348 |
Restricted stock unit withholdings |  | (9) |  |  | (323) |  |  | — |  |  | 142 |  |  | — |  |  | (181) |
Balance as of June 28, 2025 |  | $ | 4,377 |  |  | $ | 52,334 |  |  | $ | 65 |  |  | $ | 45,484 |  |  | $ | 7,868 |  |  | $ | 105,751 |
Balance as of December 30, 2023 |  | $ | 4,228 |  |  | $ | 36,649 |  |  | $ | (215) |  |  | $ | 69,156 |  |  | $ | 4,375 |  |  | $ | 109,965 |
Net income (loss) |  | — |  |  | — |  |  | — |  |  | (1,991) |  |  | (100) |  |  | (2,091) |
Other comprehensive income (loss) |  | — |  |  | — |  |  | (481) |  |  | — |  |  | — |  |  | (481) |
Net proceeds from partner contributions |  | — |  |  | 11,012 |  |  | — |  |  | — |  |  | 849 |  |  | 11,861 |
Employee equity incentive plans and other |  | 58 |  |  | 631 |  |  | — |  |  | — |  |  | — |  |  | 631 |
Share-based compensation |  | — |  |  | 1,878 |  |  | — |  |  | — |  |  | 81 |  |  | 1,959 |
Restricted stock unit withholdings |  | (10) |  |  | (407) |  |  | — |  |  | 60 |  |  | — |  |  | (347) |
Cash dividends declared ($0.25 per share of common stock) |  | — |  |  | — |  |  | — |  |  | (1,063) |  |  | — |  |  | (1,063) |
Balance as of June 29, 2024 |  | $ | 4,276 |  |  | $ | 49,763 |  |  | $ | (696) |  |  | $ | 66,162 |  |  | $ | 5,205 |  |  | $ | 120,434 |

1.The retained earnings balance as of December 28, 2024 includes an opening balance adjustment made as a result of the adoption of a new accounting standard in 2025.
See accompanying notes.

| Financial Statements | Consolidated Condensed Statements of Stockholders' Equity | 7

Table of Contents

Notes to Consolidated Condensed Financial Statements |

Note 1 : | Basis of Presentation

We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2024 Form 10-K.
We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with our 2024 Form 10-K, which includes additional information on our significant accounting policies, as well as the methods and assumptions used in our estimates. The critical accounting estimates discussed in this Form 10-Q supplement the significant accounting policies outlined in "Note 2: Accounting Policies" within Notes to Consolidated Financial Statements within our Annual Report on Form 10-K for the fiscal year ended December 28, 2024.
We made certain reclassifications within our Consolidated Condensed Financial Statements, and, in certain cases, adjusted prior periods to conform to the current period presentation. These reclassifications had no impact on previously reported net income (loss), cash flows, or stockholders' equity.

Note 2 : | Operating Segments

In the first quarter of 2025, we made an organizational change to integrate our Networking and Edge (NEX) business into CCG and DCAI and modified our segment reporting to align to this and certain other business reorganizations. All prior period segment data has been retrospectively adjusted to reflect the way our CODM internally receives information and manages and monitors our operating segment performance starting in fiscal year 2025. There are no changes to our Consolidated Financial Statements for any prior periods.
We organize and manage our business as follows:
▪Intel Products:
▪C lient Computing Group (CCG)
▪Data Center and AI (DCAI)
▪Intel Foundry
▪All Other
▪A ltera
▪M obileye
▪Other
CCG, DCAI, and Intel Foundry qualify as reportable operating segments. When we enter into federal contracts, they are aligned to the sponsoring operating segment.
The accounting policies applied to our segments follow those applied to Intel as a whole. A summary of the basis for which we report our operating segment revenues and operating margin is as follows:
Intel Products: CCG and DCAI
▪Segment revenue: Consists of revenues from external customers. Our Intel Products operating segments represent most of Intel consolidated revenue and are derived from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which are based on Intel architecture.
▪Segment expenses: Consists of intersegment charges for product manufacturing and related services from Intel Foundry, external foundry and other manufacturing expenses, product development costs, allocated expenses as described below, and direct operating expenses.
Intel Foundry
▪Segment revenue: Consists substantially of intersegment product and services revenue for wafer fabrication, substrates and other related products, and services sold to Intel Products, Altera, and certain other Intel internal businesses. We recognize intersegment revenue based on the completion of performance obligations. Product revenue is recognized upon transfer of ownership, which is generally at the completion of wafer sorting. Backend service revenue is recognized upon the completion of assembly and test milestones, which approximates the recognition of revenue over the service period. Intersegment sales are recorded at prices that are intended to approximate market pricing. Intel Foundry also includes certain third-party foundry and assembly and test revenues from external customers that totaled $22 million in the three months ended June 28, 2025 and $53 million in the first six months of 2025, compared to $39 million in the three months ended June 29, 2024, and $52 million in the first six months of 2024.

| Financial Statements | Notes to Financial Statements | 8

Table of Contents
▪Segment expenses: Consists of direct expenses for technology development, product manufacturing and services provided by Intel Foundry to internal and external customers, allocated expenses as described below, and direct operating expenses. Direct expenses for product manufacturing include excess capacity charges, if any.
All Other
Our "all other" category includes the results of operations from other non-reportable segments not otherwise presented, including our Altera and Mobileye businesses, our IMS business, start-up businesses that support our initiatives, and historical results of operations from divested businesses. The financial results of our all other category include intersegment product and services revenue and intersegment expenses primarily between our Altera and Intel Foundry segments. On April 14, 2025, we entered into an agreement to sell 51% of all issued and outstanding common stock of Altera, a wholly owned subsidiary. The transaction is expected to close in the second half of 2025, subject to regulatory approvals and other customary closing conditions. See "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements for further information.
We allocate operating expenses from our sales and marketing group to the Intel Products operating segments and allocate substantially all our operating expenses from our general and administration groups to our reportable operating segments.
We estimate that the substantial majority of our consolidated depreciation expense in the first six months of 2025 and 2024 was incurred by Intel Foundry. Intel Foundry depreciation expense is substantially included in overhead cost pools and then combined with other costs, and subsequently absorbed into inventory as each product passes through the manufacturing process and is sold to Intel Products or other customers. As a result, it is impracticable to determine the total depreciation expense included as a component of each Intel Products operating segment's operating income (loss).
We do not allocate the following corporate operating expenses to our operating segments:
▪restructuring and other charges;
▪share-based compensation;
▪certain impairment charges; and
▪certain acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill.
We do not allocate the following non-operating items to our operating segments:
▪gains and losses from equity investments;
▪interest and other income; and
▪income taxes.
Our Chief Executive Officer is our CODM. The CODM uses segment revenue and segment operating income (loss) to evaluate each segment's performance and allocate resources. These financial measures are utilized during our budgeting and forecasting process to assess profitability and enable decision making regarding strategic initiatives, capital investments, and personnel across all operating segments. Segment operating results regularly reviewed by our CODM also include total cost of sales and operating expenses directly attributable to each segment. Prior to the second quarter of 2025, our CODM regularly reviewed cost of sales and operating expenses, on a discrete basis, attributable to each segment. We have recast prior period segment operating results to reflect the significant segment-level expenses as currently reviewed by our CODM. We centrally manage all procurement, treasury, and asset management functions across the enterprise and do not maintain separate balance sheets by segment within our systems of record, nor does our CODM receive total asset information by segment for purposes of assessing segment performance and allocating resources.
Intersegment eliminations: Intersegment sales and related gross profit on inventory recorded at the end of the period or sold through to third-party customers is eliminated for consolidation purposes. The Intel Products operating segments and Intel Foundry are meant to reflect separate fabless semiconductor and foundry companies, respectively. Thus, certain intersegment activity is captured within the intersegment eliminations upon consolidation and presented at the Intel consolidated level. This activity primarily relates to inventory reserves, which are determined and recorded based on our accounting policies for Intel as a whole but are only recorded by the Intel Products operating segments upon transfer of inventory from Intel Foundry. If a reserve is identified which relates to neither Intel Products operating segments nor Intel Foundry, the reserve is recognized as activity within the intersegment eliminations for Intel on a consolidated basis.
Reporting units and goodwill reallocation: As a result of modifying our segment reporting in the first quarter of 2025, we reallocated goodwill among our affected reporting units, which generally align to our operating segment structure, on a relative fair value basis. We performed a goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization, concluding that goodwill was not impaired.
As a result of modifying our segment reporting in the first quarter of 2024, we reallocated goodwill among our affected reporting units on a relative fair value basis. We performed a quantitative goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization. We concluded based on our pre-reorganization impairment test that goodwill was not impaired. As a result of our post-reorganization impairment test, we recognized a non-cash goodwill impairment loss of $222 million in the first quarter of 2024 related to our new Intel Foundry reporting unit as the estimated fair value of the new reporting unit was lower than the assigned carrying value. Intel Foundry had no remaining allocated goodwill as of March 30, 2024, or for any subsequent reporting period.

| Financial Statements | Notes to Financial Statements | 9

Table of Contents
Net revenue, cost of sales and operating expenses, and operating income (loss) for each period were as follows:

|  | Three Months Ended
(In Millions) |  | Jun 28, 2025
|  | Intel Products |  |  |  |  |  |  |  |  |  |
|  | CCG |  | DCAI |  | Total Intel Products |  | Intel Foundry |  | All Other |  | Corporate Unallocated |  | Intersegment Eliminations |  | Total Consolidated
Revenue |  | $ | 7,871 |  |  | $ | 3,939 |  |  | $ | 11,810 |  |  | $ | 4,417 |  |  | $ | 1,053 |  |  | $ | — |  |  | $ | (4,421) |  |  | $ | 12,859 |
Cost of sales and operating expenses |  | 5,818 |  |  | 3,306 |  |  | 9,124 |  |  | 7,585 |  |  | 984 |  |  | 2,755 |  |  | (4,413) |  |  | 16,035 |
Operating income (loss) |  | $ | 2,053 |  |  | $ | 633 |  |  | $ | 2,686 |  |  | $ | (3,168) |  |  | $ | 69 |  |  | $ | (2,755) |  |  | $ | (8) |  |  | $ | (3,176) |

|  | Three Months Ended
(In Millions) |  | Jun 29, 2024
|  | Intel Products |  |  |  |  |  |  |  |  |  |
|  | CCG |  | DCAI |  | Total Intel Products |  | Intel Foundry |  | All Other |  | Corporate Unallocated |  | Intersegment Eliminations |  | Total Consolidated
Revenue |  | $ | 8,143 |  |  | $ | 3,805 |  |  | $ | 11,948 |  |  | $ | 4,282 |  |  | $ | 881 |  |  | $ | — |  |  | $ | (4,278) |  |  | $ | 12,833 |
Cost of sales and operating expenses |  | 5,502 |  |  | 3,563 |  |  | 9,065 |  |  | 7,084 |  |  | 927 |  |  | 1,708 |  |  | (3,987) |  |  | 14,797 |
Operating income (loss) |  | $ | 2,641 |  |  | $ | 242 |  |  | $ | 2,883 |  |  | $ | (2,802) |  |  | $ | (46) |  |  | $ | (1,708) |  |  | $ | (291) |  |  | $ | (1,964) |

|  | Six Months Ended
(In Millions) |  | Jun 28, 2025
|  | Intel Products |  |  |  |  |  |  |  |  |  |
|  | CCG |  | DCAI |  | Total Intel Products |  | Intel Foundry |  | All Other |  | Corporate Unallocated |  | Intersegment Eliminations |  | Total Consolidated
Revenue |  | $ | 15,500 |  |  | $ | 8,065 |  |  | $ | 23,565 |  |  | $ | 9,084 |  |  | $ | 1,996 |  |  | $ | — |  |  | $ | (9,119) |  |  | $ | 25,526 |
Cost of sales and operating expenses |  | 11,086 |  |  | 6,857 |  |  | 17,943 |  |  | 14,572 |  |  | 1,824 |  |  | 4,015 |  |  | (9,351) |  |  | 29,003 |
Operating income (loss) |  | $ | 4,414 |  |  | $ | 1,208 |  |  | $ | 5,622 |  |  | $ | (5,488) |  |  | $ | 172 |  |  | $ | (4,015) |  |  | $ | 232 |  |  | $ | (3,477) |

|  | Six Months Ended
(In Millions) |  | Jun 29, 2024
|  | Intel Products |  |  |  |  |  |  |  |  |  |
|  | CCG |  | DCAI |  | Total Intel Products |  | Intel Foundry |  | All Other |  | Corporate Unallocated |  | Intersegment Eliminations |  | Total Consolidated
Revenue |  | $ | 16,416 |  |  | $ | 7,633 |  |  | $ | 24,049 |  |  | $ | 8,638 |  |  | $ | 1,524 |  |  | $ | — |  |  | $ | (8,654) |  |  | $ | 25,557 |
Cost of sales and operating expenses |  | 10,953 |  |  | 6,974 |  |  | 17,927 |  |  | 13,881 |  |  | 1,740 |  |  | 3,895 |  |  | (8,853) |  |  | 28,590 |
Operating income (loss) |  | $ | 5,463 |  |  | $ | 659 |  |  | $ | 6,122 |  |  | $ | (5,243) |  |  | $ | (216) |  |  | $ | (3,895) |  |  | $ | 199 |  |  | $ | (3,033) |

| Financial Statements | Notes to Financial Statements | 10

Table of Contents
Corporate Unallocated Expenses
Corporate unallocated expenses include certain operating expenses not allocated to specific operating segments. The nature of these expenses may vary, but primarily consist of restructuring and other charges, share-based compensation, certain impairment charges, and certain acquisition-related costs.

|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 | Jun 28, 2025 |  | Jun 29, 2024
Acquisition-related costs |  | $ | 119 |  |  | $ | 265 |  |  | $ | 270 |  |  | $ | 530 |
Share-based compensation |  | 664 |  |  | 780 |  |  | 1,348 |  |  | 1,959 |
Restructuring and other charges 1 |  | 1,890 |  |  | 943 |  |  | 2,046 |  |  | 1,291 |
Other |  | 82 |  |  | (280) |  |  | 351 |  |  | 115 |
Total corporate unallocated expenses |  | $ | 2,755 |  |  | $ | 1,708 |  |  | $ | 4,015 |  |  | $ | 3,895 |

1 See "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements for further information.

Note 3 : | Non-Controlling Interests

|  | Non-Controlling Ownership %
|  | Jun 28, 2025 |  | Jun 29, 2024 |  |
Ireland SCIP |  | 49 | % |  | 49 | % |  |
Arizona SCIP |  | 49 | % |  | 49 | % |  |
Mobileye |  | 13 | % |  | 12 | % |  |
IMS |  | 32 | % |  | 32 | % |  |

(In Millions) |  | Ireland SCIP |  | Arizona SCIP |  | Mobileye |  | IMS |  | Total
Non-controlling interests as of Dec 28, 2024 |  | $ | 61 |  |  | $ | 3,888 |  |  | $ | 1,672 |  |  | $ | 141 |  |  | $ | 5,762 |
Partner contributions |  | — |  |  | 2,240 |  |  | — |  |  | — |  |  | 2,240 |
Partner distributions |  | (91) |  |  | — |  |  | — |  |  | — |  |  | (91) |
Changes in equity of non-controlling interest holders |  | — |  |  | — |  |  | 129 |  |  | — |  |  | 129 |
Net income (loss) attributable to non-controlling interests |  | 98 |  |  | (232) |  |  | (19) |  |  | (19) |  |  | (172) |
Non-controlling interests as of Jun 28, 2025 |  | $ | 68 |  |  | $ | 5,896 |  |  | $ | 1,782 |  |  | $ | 122 |  |  | $ | 7,868 |

(In Millions) |  | Ireland SCIP |  | Arizona SCIP |  | Mobileye |  | IMS |  | Total
Non-controlling interests as of Dec 30, 2023 |  | $ | — |  |  | $ | 2,359 |  |  | $ | 1,838 |  |  | $ | 178 |  |  | $ | 4,375 |
Partner contributions |  | — |  |  | 849 |  |  | — |  |  | — |  |  | 849 |
Changes in equity of non-controlling interest holders |  | — |  |  | — |  |  | 81 |  |  | — |  |  | 81 |
Net income (loss) attributable to non-controlling interests |  | 6 |  |  | (56) |  |  | (33) |  |  | (17) |  |  | (100) |
Non-controlling interests as of Jun 29, 2024 |  | $ | 6 |  |  | $ | 3,152 |  |  | $ | 1,886 |  |  | $ | 161 |  |  | $ | 5,205 |

| Financial Statements | Notes to Financial Statements | 11

Table of Contents
Semiconductor Co-Investment Program
Ireland SCIP
We consolidate the results of an Irish limited liability company (Ireland SCIP), a VIE, into our Consolidated Condensed Financial Statements because we are the primary beneficiary. Generally, distributions will be received from Ireland SCIP based on each investor's respective ownership of Ireland SCIP, of which Intel's is 51%. Ireland SCIP has rights to factory output of an Intel owned wafer fabrication plant in Ireland (Fab 34) and rights to resell the factory output to us. We retain sole ownership of Fab 34 and we are engaged as the Fab 34 operator in exchange for variable payments from Ireland SCIP based on the related factory output. We are required to substantially complete construction of Fab 34 in accordance with contractual parameters and timelines or we will be required to pay delay-related liquidated damages to Apollo, the other investor, beginning in 2026, not to exceed $1.1 billion in total. Though we expect certain construction delays in the near term, we intend to complete construction of Fab 34. We will be required to purchase minimum quantities of the related factory output from Ireland SCIP, or we will be subject to certain volume-related damages payable to Ireland SCIP, beginning at the earlier of when construction is complete or the third quarter of 2027. As of June 28, 2025, other than cash and cash equivalents held by Ireland SCIP, most of the remaining assets and liabilities of Ireland SCIP were eliminated in our Consolidated Condensed Balance Sheets.
Arizona SCIP
We consolidate the results of an Arizona limited liability company (Arizona SCIP), a VIE, into our Consolidated Condensed Financial Statements because we are the primary beneficiary. Generally, contributions will be made to, and distributions will be received from Arizona SCIP based on our and Brookfield's proportional ownership of Arizona SCIP; we will be the sole operator and main beneficiary of two new chip factories that are being constructed by Arizona SCIP; and we will be required to both operate Arizona SCIP at minimum production levels (measured in wafer starts per week) and limit excess inventory held on site or we will be subject to certain volume-related damages payable to Arizona SCIP. The assets held by Arizona SCIP, which are not available to us as they can be used only to settle obligations of the VIE and substantially consisted of property, plant, and equipment, were $15.5 billion as of June 28, 2025 ($11.5 billion as of December 28, 2024). The remaining assets and liabilities of Arizona SCIP were eliminated in our Consolidated Condensed Balance Sheets.
Mobileye
On July 11, 2025, we converted 113.7 million of our Mobileye Class B shares into Class A shares. We subsequently sold 57.5 million of the Class A shares in a secondary offering, representing 7% of Mobileye's outstanding capital stock, for $16.50 per share and received net proceeds of $922 million. Concurrently, we sold 6.2 million of the Class A Shares directly to Mobileye. As we will continue to consolidate the results of Mobileye, the impact of their share repurchase was eliminated in our Consolidated Condensed Financial Statements.

Note 4 : | Earnings (Loss) Per Share

We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period, if applicable.

|  | Three Months Ended |  | Six Months Ended
(In Millions, Except Per Share Amounts) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Net income (loss) |  | $ | (3,024) |  |  | $ | (1,654) |  |  | $ | (3,911) |  |  | $ | (2,091) |
Less: net income (loss) attributable to non-controlling interests |  | (106) |  |  | (44) |  |  | (172) |  |  | (100) |
Net income (loss) attributable to Intel |  | $ | (2,918) |  |  | $ | (1,610) |  |  | $ | (3,739) |  |  | $ | (1,991) |
Weighted average shares of common stock outstanding—basic |  | 4,369 |  |  | 4,267 |  |  | 4,356 |  |  | 4,254 |
Weighted average shares of common stock outstanding—diluted |  | 4,369 |  |  | 4,267 |  |  | 4,356 |  |  | 4,254 |
Earnings (loss) per share attributable to Intel—basic |  | $ | (0.67) |  |  | $ | (0.38) |  |  | $ | (0.86) |  |  | $ | (0.47) |
Earnings (loss) per share attributable to Intel—diluted |  | $ | (0.67) |  |  | $ | (0.38) |  |  | $ | (0.86) |  |  | $ | (0.47) |

Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. The potentially dilutive impact from the assumed issuance of common stock associated with a contractual conversion feature is determined by applying the if-converted method to the assumed exercise of the outstanding conversion feature.

| Financial Statements | Notes to Financial Statements | 12

Table of Contents
Due to our net losses in the three and six months ended June 28, 2025 and June 29, 2024, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, the assumed issuance of common stock under the stock purchase plan, and the assumed issuance of common stock associated with a contractual conversion feature, as applicable, had anti-dilutive effects on diluted loss per share and were excluded from the computations of diluted loss per share. In the three months ended June 28, 2025, securities that would have been anti-dilutive were insignificant and in the six months ended June 28, 2025, 158 million anti-dilutive shares were excluded from the computation of earnings (loss) per share. In the three and six months ended June 29, 2024, securities that would have been anti-dilutive were insignificant.

Note 5 : | Other Financial Statement Details

Accounts Receivable
We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $1.6 billion during the first six months of 2025 ($1.0 billion during the first six months of 2024). After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution.
Inventories

(In Millions) |  | Jun 28, 2025 |  | Dec 28, 2024
Raw materials |  | $ | 1,194 |  |  | $ | 1,344 |
Work in process |  | 6,484 |  |  | 7,432 |
Finished goods |  | 3,699 |  |  | 3,422 |
Total inventories |  | $ | 11,377 |  |  | $ | 12,198 |

Property, Plant, and Equipment
We invest in and deploy manufacturing assets in response to manufacturing capacity requirements based upon short- and long-term demand forecasts and economic returns relative to capital outlays. We regularly monitor, evaluate, and adjust our manufacturing capacity footprint in response to a number of volatile factors that impact our business, including demand for our products and services and the state of the semiconductor industry as a whole. In connection with the preparation of our Consolidated Condensed Financial Statements for the second quarter of 2025, we evaluated our current process technology node capacities relative to projected market demand for our products and services, concluding that our manufacturing asset portfolio exceeded manufacturing capacity requirements. Upon performing a re-use assessment, we impaired and accelerated depreciation for certain manufacturing assets. In total, we recorded non-cash impairments and accelerated depreciation charges of $460 million and $337 million, respectively, in the second quarter of 2025, net of certain items. All charges were recognized in cost of sales within our Intel Foundry operating segment.
We also incurred $416 million of other non-cash asset impairment and accelerated depreciation charges as a direct result of the 2025 Restructuring Plan (see "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements). These charges were included as a component of "corporate unallocated expenses" within the restructuring and other category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements.
Other Accrued Liabilities
Other accrued liabilities include deferred compensation of $3.0 billion as of June 28, 2025 ($3.3 billion as of December 28, 2024).
Interest and Other, Net

|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Interest income |  | $ | 210 |  |  | $ | 320 |  |  | $ | 455 |  |  | $ | 643 |
Interest expense |  | (227) |  |  | (294) |  |  | (526) |  |  | (552) |
Other, net |  | (78) |  |  | 54 |  |  | (197) |  |  | 134 |
Total interest and other, net |  | $ | (95) |  |  | $ | 80 |  |  | $ | (268) |  |  | $ | 225 |

Interest expense is net of $368 million of interest capitalized in the second quarter of 2025 and $680 million in the first six months of 2025 ($374 million in the second quarter of 2024 and $737 million in the first six months of 2024).
Other, net includes a $94 million charge in the first six months of 2025 related to the sale of our NAND memory business (refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements).

| Financial Statements | Notes to Financial Statements | 13

Table of Contents
Government Incentives
In the first six months of 2025, we recognized $890 million in grants under the CHIPS Act, of which capital-related incentives reduced gross property, plant and equipment by $742 million, and operating-related incentives benefited operating income by $148 million, substantially all of which was recorded in cost of sales. Of the $148 million operating grants recognized in the first six months of 2025, $60 million was recognized in the second quarter of 2025. Additionally, in the first six months of 2025 we recognized an advanced manufacturing investment tax credit of $759 million ($1.3 billion in the first six months of 2024), which may be refunded to us in cash to the extent it exceeds our outstanding income tax liabilities.

Note 6 : | Restructuring and Other Charges

|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Employee severance and benefit arrangements |  | $ | 1,466 |  |  | $ | 165 |  |  | $ | 1,607 |  |  | $ | 294 |
Litigation charges and other |  | 8 |  |  | 778 |  |  | 20 |  |  | 778 |
Asset impairment charges |  | 416 |  |  | — |  |  | 419 |  |  | 219 |
Total restructuring and other charges |  | $ | 1,890 |  |  | $ | 943 |  |  | $ | 2,046 |  |  | $ | 1,291 |

In the second quarter of 2025, we announced and commenced the 2025 Restructuring Plan, which was subsequently approved and committed to by our management. This initiative is intended to lower expenses, streamline our organizational structure and reduce management layers across functions while reallocating resources toward our core client and server businesses by reducing lower-priority programs and initiatives. Restructuring charges are primarily comprised of employee severance and benefit arrangements, non-cash asset impairment and accelerated depreciation charges resulting from exit activities, as well as impairment charges relating to real estate exits and consolidations. These charges were included as "corporate unallocated expenses" within the restructuring and other category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements. We expect to recognize total charges of approximately $1.9 billion under the 2025 Restructuring Plan, the substantial majority of which will be cash settled in future periods. The cumulative cost of the 2025 Restructuring Plan as of June 28, 2025 was $1.8 billion. Any changes to our estimates or timing will be reflected in our results of operations in future periods. We expect actions pursuant to the 2025 Restructuring Plan to be substantially complete by the fourth quarter of 2025, which is subject to change.
In the third quarter of 2024, the 2024 Restructuring Plan was announced and a series of cost and capital reduction initiatives was implemented. We have incurred total charges of approximately $3.0 billion under the 2024 Restructuring Plan, which was substantially complete in the second quarter of 2025.
Employee severance and benefit arrangements included net charges of $1.4 billion during the three months ended June 28, 2025 related to the 2025 Restructuring Plan and the remaining charges for the three and six months ended June 28, 2025 primarily related to the 2024 Restructuring Plan. Additionally, we incurred charges of $165 million and $294 million during the three and six months ended June 29, 2024 related to other actions taken to streamline operations and reduce costs.
Restructuring activities related to employee severance and benefit arrangements under the 2025 Restructuring Plan and 2024 Restructuring Plan were as follows:

(In Millions) |  | 2025 Restructuring Plan |  | 2024 Restructuring Plan
Accrued restructuring balance as of December 28, 2024 |  | $ | — |  |  | $ | 302 |
Accruals and adjustments |  | 1,361 |  |  | 195 |
Cash payments |  | (11) |  |  | (417) |
Accrued restructuring balance as of June 28, 2025 |  | $ | 1,350 |  |  | $ | 80 |

The accrued restructuring balance as of June 28, 2025 and December 28, 2024 was recorded as a current liability within accrued compensation and benefits on the Consolidated Condensed Balance Sheets.
Litigation charges and other included a charge of $780 million in the second quarter of 2024 arising out of the R2 litigation. Refer to "Note 19: Commitments and Contingencies" within Notes to Consolidated Financial Statements as included in our Annual Report on Form 10-K for the year ended December 28, 2024 for further information.
Asset impairment charges in the first six months of 2025 primarily included non-cash charges associated with the 2025 Restructuring Plan resulting from the exit of certain non-core lines of business and the consolidation and exit of certain real estate properties. In addition, we also incurred a goodwill impairment loss of $222 million in the first six months of 2024 related to our Intel Foundry reporting unit (refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for further information).

| Financial Statements | Notes to Financial Statements | 14

Table of Contents

Note 7 : | Income Taxes

|  | Three Months Ended |  | Six Months Ended
($ In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Income (loss) before taxes |  | $ | (2,769) |  |  | $ | (2,004) |  |  | $ | (3,355) |  |  | $ | (2,723) |
Provision for (benefit from) taxes |  | $ | 255 |  |  | $ | (350) |  |  | $ | 556 |  |  | $ | (632) |
Effective tax rate |  | (9.2) | % |  | 17.5 | % |  | (16.6) | % |  | 23.2 | %

In the three and six months ended June 28, 2025, our provision for income taxes was determined using our estimated annual effective tax rate applied to our year-to-date ordinary income (loss) before taxes, adjusted for discrete items. We were also not able to benefit our current year loss before taxes due to the domestic valuation allowance first recorded in Q3 2024.
In the three and six months ended June 29, 2024, due to our inability to reliably forecast our annual income, our benefit from income taxes was determined using a three and six month actual annual effective tax rate, respectively, adjusted for discrete items.
On July 4, 2025, the One Big Beautiful Bill Act ("the Act") was signed into law. The Act makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation and domestic research cost expensing, increases the Advanced Manufacturing Investment Credit to 35 percent from 25 percent, and makes modifications to the international tax framework. We are currently evaluating the impact of the Act upon our future effective tax rate, tax liabilities, and cash taxes.

Note 8 : | Investments

Short-term Investments
Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within cash and cash equivalents and short-term investments on the Consolidated Condensed Balance Sheets. Government debt includes instruments such as non-US government bills and bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of June 28, 2025 and December 28, 2024, substantially all time deposits were issued by institutions outside the US.
For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in interest and other, net. The fair value of our economically hedged marketable debt investments was $11.1 billion as of June 28, 2025 ($13.5 billion as of December 28, 2024). For hedged investments still held at the reporting date, we recorded net gains of $329 million in the second quarter of 2025 and net gains of $491 million in the first six months of 2025 ($139 million of net losses in the second quarter of 2024 and net losses of $366 million in the first six months of 2024).
Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) and realized gains or losses recorded in interest and other, net. The adjusted cost of our unhedged investments was $6.1 billion as of June 28, 2025 ($5.2 billion as of December 28, 2024), which approximated the fair value at these dates.
The fair value of marketable debt investments, by contractual maturity, as of June 28, 2025, was as follows:

(In Millions) |  | Fair Value
Due in 1 year or less |  | $ | 5,580 |
Due in 1–2 years |  | 2,979 |
Due in 2–5 years |  | 5,314 |
Due after 5 years |  | 234 |
Instruments not due at a single maturity date 1 |  | 3,165 |
Total |  | $ | 17,272 |

1 "Instruments not due at a single maturity date" is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents.

| Financial Statements | Notes to Financial Statements | 15

Table of Contents
Equity Investments

(In Millions) |  | Jun 28, 2025 |  | Dec 28, 2024
Marketable equity investments 1 |  | $ | 467 |  |  | $ | 848 |
Non-marketable equity investments |  | 4,916 |  |  | 4,535 |
Total |  | $ | 5,383 |  |  | $ | 5,383 |

1 Substantial majority of our marketable equity investments are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
The components of gains (losses) on equity investments, net for each period were as follows:

|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Unrealized gains (losses) on marketable equity investments |  | $ | (58) |  |  | $ | (222) |  |  | $ | (350) |  |  | $ | 30 |
Unrealized gains (losses) on non-marketable equity investments 1 |  | 473 |  |  | 24 |  |  | 473 |  |  | 48 |
Impairment charges |  | (51) |  |  | (91) |  |  | (156) |  |  | (159) |
Unrealized gains (losses) on equity investments, net |  | 364 |  |  | (289) |  |  | (33) |  |  | (81) |
Realized gains (losses) on sales of equity investments, net |  | 138 |  |  | 169 |  |  | 423 |  |  | 166 |
Gains (losses) on equity investments, net |  | $ | 502 |  |  | $ | (120) |  |  | $ | 390 |  |  | $ | 85 |

1 Unrealized gains (losses) on non-marketable investments includes observable price adjustments and our share of equity method investee gains (losses) and certain distributions.
In the second quarter of 2025, we recognized upward observable price adjustments of $469 million within g ains (losses) on equity investments, net, of which $396 million related to a single investee.

Note 9 : | Divestitures

NAND Memory Business
We sold our NAND memory technology and manufacturing business to SK hynix Inc. (SK hynix) which we deconsolidated upon closing the first phase of the transaction on December 29, 2021. On March 27, 2025, we closed the second phase of the transaction, collected the outstanding receivable, and recorded proceeds of $1.9 billion within cash and cash equivalents, net of certain adjustments.
In connection with the second closing, we entered into a final release and settlement agreement with SK hynix primarily related to certain penalties associated with the manufacturing and sale agreement between us and SK hynix, recognizing a net charge of $94 million within Interest and other, net for the amount paid to SK hynix during the first quarter of 2025.
Altera FPGA Business
On April 14, 2025, we signed a transaction agreement with SLP VII Gryphon Aggregator, L.P., an affiliate of Silver Lake Partners (SLP), to sell 51% of all issued and outstanding common stock of Altera, a wholly owned subsidiary. The transaction is expected to close in the second half of 2025, subject to regulatory approvals and other customary closing conditions, and is expected to result in the receipt of net cash proceeds of approximately $4.4 billion, after adjusting for certain amounts that we bear responsibility for pursuant to the transaction agreement, including the separation costs described below. Pursuant to the transaction agreement, $1.0 billion of the purchase price will be deferred and payable to us in two equal $500 million installments no later than December 31, 2026 and December 31, 2027. Receipt of the deferred consideration is not subject to any contingencies. Upon closing the transaction, we will retain a 49% minority investment in Altera.
Contemporaneously with the execution of the transaction agreement, we entered into a separation agreement with SLP that sets forth the terms for the completion of the separation of Altera from Intel to operate on a standalone basis, including our agreement to fund separation costs and expenses up to an aggregate amount of $277 million. In connection with the transaction, we anticipate entering into certain ancillary agreements that govern, among other things, intellectual property rights, employee matters, government contracting, and a wafer manufacturing and sale agreement pursuant to which we will provide semiconductor wafer manufacturing services to Altera.
Based on the terms of the transaction agreement, we have concluded that upon transaction close, Altera will be a VIE for which we are not the primary beneficiary because the governance structure of the entity does not allow us to direct the activities that would most significantly impact Altera's economic performance. At transaction close, we will deconsolidate Altera from our consolidated financial statements, record the cash proceeds received and a receivable of up to $1.0 billion of deferred cash proceeds, and recognize our remaining minority investment in Altera at fair value and prospectively apply the equity method of accounting for the investment.

| Financial Statements | Notes to Financial Statements | 16

Table of Contents
The carrying amounts of the major classes of Altera's assets and liabilities held for sale, which are classified as other current assets and o ther current liabilities, respectively, within the Consolidated Condensed Balance Sheets, included the following:

(In Millions) |  | Jun 28, 2025
Assets |  |
Cash and cash equivalents |  | $ | 50 |
Inventories |  | 711 |
Property, plant and equipment, net |  | 197 |
Identified intangible assets, net |  | 394 |
Goodwill |  | 781 |
Other assets |  | 177 |
Total assets held for sale |  | $ | 2,310 |
Liabilities |  |
Accrued compensation and benefits |  | $ | 131 |
Other liabilities |  | 173 |
Total liabilities held for sale |  | $ | 304 |

In the second quarter of 2025, we ceased recording depreciation and amortization on property, plant, and equipment and identified intangible assets as of the date the assets were designated as held for sale.

Note 10 : | Borrowings

In the first quarter of 2025, we amended our 364-day $8.0 billion credit facility agreement to $5.0 billion, and the maturity date was extended by one year to January 2026. Neither of our revolving credit facilities had borrowings outstanding as of June 28, 2025 or December 28, 2024.
We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. In the first six months of 2025, we borrowed $3.5 billion and settled $1.5 billion of our commercial paper and had $2.0 billion of 4.60% commercial paper outstanding as of June 28, 2025 (no commercial paper outstanding as December 28, 2024). Borrowings under the commercial paper program are unsecured general obligations.

| Financial Statements | Notes to Financial Statements | 17

Table of Contents

Note 11 : | Fair Value

Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis

|  | Jun 28, 2025 |  | Dec 28, 2024 |  |
|  | Fair Value Measured and Recorded at Reporting Date Using |  |  |  | Fair Value Measured and Recorded at Reporting Date Using |  |  |  |
(In Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt |  | $ | — |  |  | $ | 1,125 |  |  | $ | — |  |  | $ | 1,125 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  |
Financial institution instruments¹ |  | 3,017 |  |  | 1,567 |  |  | — |  |  | 4,584 |  |  | 4,121 |  |  | 743 |  |  | — |  |  | 4,864 |  |  |
Reverse repurchase agreements |  | — |  |  | 3,204 |  |  | — |  |  | 3,204 |  |  | — |  |  | 2,654 |  |  | — |  |  | 2,654 |  |  |
Short-term investments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt |  | — |  |  | 6,112 |  |  | — |  |  | 6,112 |  |  | — |  |  | 5,365 |  |  | — |  |  | 5,365 |  |  |
Financial institution instruments¹ |  | 148 |  |  | 3,165 |  |  | — |  |  | 3,313 |  |  | 195 |  |  | 3,356 |  |  | — |  |  | 3,551 |  |  |
Government debt² |  | 44 |  |  | 2,094 |  |  | — |  |  | 2,138 |  |  | 33 |  |  | 4,864 |  |  | — |  |  | 4,897 |  |  |
Other current assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative assets |  | 143 |  |  | 836 |  |  | — |  |  | 979 |  |  | 348 |  |  | 733 |  |  | — |  |  | 1,081 |  |  |
Marketable equity investments |  | 467 |  |  | — |  |  | — |  |  | 467 |  |  | 848 |  |  | — |  |  | — |  |  | 848 |  |  |
Other long-term assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative assets |  | — |  |  | 4 |  |  | — |  |  | 4 |  |  | — |  |  | 1 |  |  | — |  |  | 1 |  |  |
Total assets measured and recorded at fair value |  | $ | 3,819 |  |  | $ | 18,107 |  |  | $ | — |  |  | $ | 21,926 |  |  | $ | 5,545 |  |  | $ | 17,716 |  |  | $ | — |  |  | $ | 23,261 |  |  |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other accrued liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities |  | $ | — |  |  | $ | 390 |  |  | $ | 124 |  |  | $ | 514 |  |  | $ | — |  |  | $ | 562 |  |  | $ | 134 |  |  | $ | 696 |  |  |
Other long-term liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities³ |  | — |  |  | 188 |  |  | 755 |  |  | 943 |  |  | — |  |  | 416 |  |  | 755 |  |  | 1,171 |  |  |
Total liabilities measured and recorded at fair value |  | $ | — |  |  | $ | 578 |  |  | $ | 879 |  |  | $ | 1,457 |  |  | $ | — |  |  | $ | 978 |  |  | $ | 889 |  |  | $ | 1,867 |  |  |

1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of time deposits, notes, and bonds issued by financial institutions.
2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt.
3 Level 3 derivative liabilities include liquidated damage provisions related to our Ireland SCIP arrangement.
Assets Measured and Recorded at Fair Value on a Non-Recurring Basis
Our non-marketable equity investments, equity method investments, and certain non-financial assets—such as intangible assets, goodwill, and property, plant, and equipment—are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity investments during the period, we classify these assets as Level 3. Similarly, impairments recognized on our goodwill, intangible assets, and property, plant, and equipment are categorized as Level 3 within the fair value hierarchy as we utilize unobservable inputs such as prospective financial information, market segment growth rates, and discount rates in the fair value measurement process.
Financial Instruments Not Recorded at Fair Value on a Recurring Basis
Financial instruments not recorded at fair value on a recurring basis include non-marketable equity investments and equity method investments that have not been remeasured or impaired in the current period, grants receivable, and issued debt.
We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial assets approximates their carrying value. The aggregate carrying value of grants receivable as of June 28, 2025, was $853 million (the aggregate carrying value of grants receivable as of December 28, 2024, was $1.7 billion).
We classify the fair value of issued debt (excluding any commercial paper) as Level 2. The fair value of these instruments was $43.3 billion as of June 28, 2025 ($43.5 billion as of December 28, 2024).

| Financial Statements | Notes to Financial Statements | 18

Table of Contents

Note 12 : | Derivative Financial Instruments

Volume of Derivative Activity
Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows:

(In Millions) |  | Jun 28, 2025 |  | Dec 28, 2024 |  |
Foreign currency contracts |  | $ | 18,123 |  |  | $ | 25,472 |  |  |
Interest rate contracts |  | 18,236 |  |  | 17,899 |  |  |
Other |  | 2,467 |  |  | 2,593 |  |  |
Total |  | $ | 38,826 |  |  | $ | 45,964 |  |  |

The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of June 28, 2025 and December 28, 2024.
Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets

|  | Jun 28, 2025 |  | Dec 28, 2024
(In Millions) |  | Assets 1 |  | Liabilities 2 |  | Assets 1 |  | Liabilities 2
Derivatives designated as hedging instruments: |  |  |  |  |  |  |  |
Foreign currency contracts 3 |  | $ | 392 |  |  | $ | 11 |  |  | $ | 40 |  |  | $ | 405 |
Interest rate contracts |  | — |  |  | 335 |  |  | — |  |  | 582 |
Total derivatives designated as hedging instruments |  | $ | 392 |  |  | $ | 346 |  |  | $ | 40 |  |  | $ | 987 |
Derivatives not designated as hedging instruments: |  |  |  |  |  |  |  |
Foreign currency contracts 3 |  | $ | 343 |  |  | $ | 279 |  |  | $ | 510 |  |  | $ | 100 |
Interest rate contracts |  | 105 |  |  | 77 |  |  | 184 |  |  | 25 |
Equity contracts |  | 143 |  |  | — |  |  | 348 |  |  | — |
Other 4 |  | — |  |  | 755 |  |  | — |  |  | 755 |
Total derivatives not designated as hedging instruments |  | $ | 591 |  |  | $ | 1,111 |  |  | $ | 1,042 |  |  | $ | 880 |
Total derivatives |  | $ | 983 |  |  | $ | 1,457 |  |  | $ | 1,082 |  |  | $ | 1,867 |

1 Derivative assets are recorded as other assets, current and long-term.
2 Derivative liabilities are recorded as other liabilities, current and long-term.
3 A substantial majority of these instruments mature within 12 months.
4 Embedded derivative related to our Ireland SCIP arrangement.

| Financial Statements | Notes to Financial Statements | 19

Table of Contents
Amounts Offset in the Consolidated Condensed Balance Sheets
Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows:

|  | Jun 28, 2025 |  |  |  |
|  |  |  |  |  |  |  | Gross Amounts Not Offset in the Balance Sheet |  |  |  |  |  |
(In Millions) |  | Gross Amounts Recognized |  | Gross Amounts Offset in the Balance Sheet |  | Net Amounts Presented in the Balance Sheet |  | Financial Instruments |  | Cash and Non-Cash Collateral Received or Pledged |  | Net Amount |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative assets subject to master netting arrangements |  | $ | 858 |  |  | $ | — |  |  | $ | 858 |  |  | $ | (391) |  |  | $ | (467) |  |  | $ | — |  |  |  |  |
Reverse repurchase agreements |  | 3,204 |  |  | — |  |  | 3,204 |  |  | — |  |  | (3,204) |  |  | — |  |  |  |  |
Total assets |  | $ | 4,062 |  |  | $ | — |  |  | $ | 4,062 |  |  | $ | (391) |  |  | $ | (3,671) |  |  | $ | — |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities subject to master netting arrangements |  | $ | 677 |  |  | $ | — |  |  | $ | 677 |  |  | $ | (391) |  |  | $ | (269) |  |  | $ | 17 |  |  |  |  |
Total liabilities |  | $ | 677 |  |  | $ | — |  |  | $ | 677 |  |  | $ | (391) |  |  | $ | (269) |  |  | $ | 17 |  |  |  |  |

|  | Dec 28, 2024
|  |  |  |  |  |  |  | Gross Amounts Not Offset in the Balance Sheet |  |
(In Millions) |  | Gross Amounts Recognized |  | Gross Amounts Offset in the Balance Sheet |  | Net Amounts Presented in the Balance Sheet |  | Financial Instruments |  | Cash and Non-Cash Collateral Received or Pledged |  | Net Amount
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Derivative assets subject to master netting arrangements |  | $ | 948 |  |  | $ | — |  |  | $ | 948 |  |  | $ | (269) |  |  | $ | (679) |  |  | $ | — |
Reverse repurchase agreements |  | 2,654 |  |  | — |  |  | 2,654 |  |  | — |  |  | (2,654) |  |  | — |
Total assets |  | $ | 3,602 |  |  | $ | — |  |  | $ | 3,602 |  |  | $ | (269) |  |  | $ | (3,333) |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities subject to master netting arrangements |  | $ | 1,084 |  |  | $ | — |  |  | $ | 1,084 |  |  | $ | (269) |  |  | $ | (745) |  |  | $ | 70 |
Total liabilities |  | $ | 1,084 |  |  | $ | — |  |  | $ | 1,084 |  |  | $ | (269) |  |  | $ | (745) |  |  | $ | 70 |

We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate.
Derivatives in Cash Flow Hedging Relationships
The before-tax net gains or losses attributed to the effective portion of cash flow hedges recognized in other comprehensive income (loss) were $533 million net gains in the second quarter of 2025 and $713 million net gains in the first six months of 2025 ($227 million net losses in the second quarter of 2024 and $658 million net losses in the first six months of 2024).

| Financial Statements | Notes to Financial Statements | 20

Table of Contents
Derivatives in Fair Value Hedging Relationships
The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows:

|  | Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Operations
|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Interest rate contracts |  | $ | 106 |  |  | $ | 24 |  |  | $ | 247 |  |  | $ | (120) |
Hedged items |  | (106) |  |  | (24) |  |  | (247) |  |  | 120 |
Total |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |

The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows:

Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included |  | Carrying Amount of the Hedged Item Assets/(Liabilities) |  | Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities)
(In Millions) |  | Jun 28, 2025 |  | Dec 28, 2024 |  | Jun 28, 2025 |  | Dec 28, 2024 |
Short-term debt |  | $ | (3,227) |  |  | $ | (2,214) |  |  | $ | 23 |  |  | $ | 36 |  |
Long-term debt |  | (8,435) |  |  | (9,201) |  |  | 312 |  |  | 546 |  |
Total |  | $ | (11,662) |  |  | $ | (11,415) |  |  | $ | 335 |  |  | $ | 582 |  |

Derivatives Not Designated as Hedging Instruments
The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Operations for each period were as follows:

|  |  |  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Location of Gains (Losses) Recognized in Income on Derivatives |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Foreign currency contracts |  | Interest and other, net |  | $ | (19) |  |  | $ | 190 |  |  | $ | (104) |  |  | $ | 536 |
Interest rate contracts |  | Interest and other, net |  | (28) |  |  | 34 |  |  | (85) |  |  | 151 |
Other |  | Various |  | 199 |  |  | 56 |  |  | 42 |  |  | 193 |
Total |  |  |  | $ | 152 |  |  | $ | 280 |  |  | $ | (147) |  |  | $ | 880 |

Note 13 : | Contingencies

Legal Proceedings
We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. As of June 28, 2025, we have accrued a charge of $1.0 billion related to litigation involving VLSI and a charge of $401 million related to an EC-imposed fine, both as described below. Excluding the VLSI claims described below, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Unless specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time.

| Financial Statements | Notes to Financial Statements | 21

Table of Contents
European Commission Competition Matter
In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged “conditional rebates and payments” that required customers to purchase all or most of their x86 microprocessors from us and by making alleged “payments to prevent sales of specific rival products.” The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009.
We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC's 2009 findings against us regarding rebates, as well as the €1.1 billion fine imposed on Intel, which was returned to us in February 2022. The General Court's January 2022 decision did not annul the EC's 2009 finding that we made payments to prevent sales of specific rival products.
In April 2022, the EC appealed the General Court's findings regarding rebates to the Court of Justice. In October 2024, the Court of Justice dismissed the EC's appeal, upholding the judgment of the General Court.
In September 2023, the EC imposed a €376 million ($401 million) fine against us based on its 2009 finding that we made payments to prevent sales of specific rival products. We have appealed the EC's decision. We have accrued a charge for the fine and are unable to make a reasonable estimate of the potential loss or range of losses in excess of this amount given the procedural posture and the nature of these proceedings.
Litigation Related to Security Vulnerabilities
In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, the first variants of which are now commonly referred to as “Spectre” and “Meltdown,” that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available.
Consumer class action lawsuits against us were pending in the US and Canada. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with Spectre, Meltdown, and other variants of this class of security vulnerabilities that have been identified since 2018, and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the US, class action suits filed in various jurisdictions between 2018 and 2021 were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs' failure to plead a viable claim. The Ninth Circuit Court of Appeals affirmed the district court's judgment in November 2023, ending the litigation. In November 2023, new plaintiffs filed a consumer class action complaint in the US District Court for the Northern District of California with respect to a further vulnerability variant disclosed in August 2023 and commonly referred to as “Downfall.” In August 2024, the district court dismissed plaintiffs' complaint for failure to plead a viable claim. Plaintiffs filed an amended complaint in September 2024, which we moved to dismiss in October 2024. In Canada, an initial status conference has not yet been scheduled in one case relating to Spectre and Meltdown pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters.
Litigation Related to Segment Reporting and Internal Foundry Model
A securities class action lawsuit was filed in the US District Court for the Northern District of California in May 2024 against us and certain officers following the modification of our segment reporting in the first quarter of 2024 to align to our new internal foundry operating model. In August 2024, the court ordered the case consolidated with a second, similar lawsuit, and in October 2024 plaintiffs filed an amended consolidated complaint generally alleging that defendants violated the federal securities laws by making false or misleading statements about the growth and prospects of the foundry business and seeking monetary damages on behalf of all persons and entities that purchased or otherwise acquired our common stock or purchased call options or sold put options on our common stock from January 25, 2024 through August 1, 2024. In early March 2025, the court granted defendants' motion to dismiss the amended consolidated complaint. The court granted plaintiffs leave to amend, and in late March 2025 plaintiffs filed a second amended complaint. In April 2025 defendants filed a motion to dismiss the second amended complaint. In July 2025, the court granted defendant’s motion to dismiss without granting plaintiffs leave to amend their complaint. Given the procedural posture of the case, including that the plaintiffs may appeal the district court's decision, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter.
Stockholder derivative lawsuits have been filed in Delaware state and federal courts alleging that our directors and certain officers breached their fiduciary duties and violated the federal securities laws by making or allowing the statements that are challenged in the securities class action lawsuit. The plaintiffs in the derivative lawsuits seek to recover damages from the defendants on behalf of Intel. By stipulation of the parties, the Delaware state and federal courts have ordered the cases before them stayed pending certain developments in the securities class action lawsuit.

| Financial Statements | Notes to Financial Statements | 22

Table of Contents
Litigation Related to Patent and IP Claims
We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business.
VLSI Technology LLC v. Intel
In October 2017, VLSI Technology LLC (VLSI) filed a complaint against us in the US District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents VLSI acquired from NXP Semiconductors, N.V. (NXP). VLSI sought damages, attorneys' fees, costs, and interest. Intel prevailed on all eight patents and the court entered final judgment in April 2024. VLSI appealed the Court's judgment of non-infringement as to one of the eight patents. In April 2019, VLSI filed three infringement suits against us in the US District Court for the Western District of Texas accusing various of our processors of infringement of eight additional patents it had acquired from NXP:
▪The first Texas case went to trial in February 2021, and the jury awarded VLSI $1.5 billion for literal infringement of one patent and $675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI $2.2 billion in damages and approximately $162 million in pre-judgment and post-judgment interest. We appealed the judgment to the Federal Circuit Court of Appeals, including the court's rejection of Intel's claim to have a license from Fortress Investment Group's acquisition of Finjan. The Federal Circuit Court heard oral argument in October 2023. In December 2023, the Federal Circuit reversed the finding of infringement as to the patent for which VLSI was awarded $675 million. The Federal Circuit affirmed the finding of infringement as to the patent for which VLSI had been awarded $1.5 billion, but vacated the damages award and sent the case back to the trial court for further damages proceedings on that patent. The Federal Circuit also ruled that Intel can advance the defense that it is licensed to VLSI's patents. In December 2021 and January 2022 the Patent Trial and Appeal Board (PTAB) instituted Inter Partes Reviews (IPR) on the claims found to have been infringed in the first Texas case, and in May and June 2023 found all of those claims unpatentable; VLSI has appealed the PTAB's decisions. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents. The motion remains pending.
▪The second Texas case went to trial in April 2021, and the jury found that we do not infringe the asserted patents. VLSI had sought approximately $3.0 billion for alleged infringement, plus enhanced damages for willful infringement. In September 2024, the court denied VLSI's motion for a new trial. Other post-trial motions remain pending, and the court has not yet entered final judgment.
▪The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately $949 million in damages, plus interest and a running royalty. The court has not yet entered final judgment. In February 2023, we filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents, and the court granted Intel's motion that same month. In May 2025, the court held a trial on an underlying factual question relating to Intel’s license defense. The jury returned a verdict in Intel's favor. Post-trial briefing is ongoing, and the court will now address the ultimate legal issue of whether Intel obtained a license to the asserted VLSI patent through Intel’s license agreement with Finjan when Fortress Investments acquired Finjan.
In May 2019, VLSI filed a case in Shenzhen Intermediate People's Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserted one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA) which held a hearing in September 2021. The Shenzhen court held trial proceedings in July 2021 and September 2023. VLSI sought an injunction as well as RMB 1.3 million in costs and expenses, but no damages. In September 2023, the CNIPA invalidated every claim of the asserted patent. In November 2023, the trial court dismissed VLSI's case.
In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel core processors. The Shanghai court held trial hearings in December 2020 and in May 2022, where VLSI requested expenses (RMB 300 thousand) and an injunction. In October 2023, the Shanghai court issued a decision finding no infringement and dismissing all claims. In November 2023, VLSI appealed the finding of non-infringement to the Supreme People's Court. The Supreme People's Court held an evidentiary hearing in October 2024, and a trial in November 2024.
In parallel in December 2022, we had filed a petition to invalidate the patent at issue in the Shanghai proceeding. In February 2024, the patent was found not invalid, and Intel appealed the decision in May 2024. After the Beijing Intellectual Property Court upheld the validity of the patent in May 2025, we filed a further appeal to the Supreme People’s Court in June 2025. Both VLSI’s appeal of the noninfringement decision and our appeal of the validity decision before the Supreme People’s Court remain pending.

| Financial Statements | Notes to Financial Statements | 23

Table of Contents
In July 2024, Intel filed suit against VLSI in US District Court for the District of Delaware requesting the court find Intel is licensed to VLSI's patents. In September 2024, VLSI filed motions requesting that Intel's complaint be dismissed, transferred, or stayed. In December 2024, the Delaware court stayed the case and deferred the pending motions until May 31, 2025.
As of June 28, 2025, we have accrued a charge of approximately $1.0 billion related to the VLSI litigation. We are unable to make a reasonable estimate of losses in excess of recorded amounts.
Eire Og Innovations v IBM et. al.
B etween April and present, EireOg Innovations Ltd. has filed eleven separate complaints in the Eastern and Western Districts of Texas against Intel and AMD customers alleging that various products with Intel and AMD CPUs infringe numerous patents. EireOg seeks compensatory damages, future royalties, attorneys’ fees, costs, and interest. Intel is indemnifying Acer, Amazon Web Services (AWS), Cisco, Dell, HPE, HPI, IBM, Lenovo, and Oracle in connection with Intel CPUs accused of infringing four patents. Cisco and IBM filed their answers in June 2024. In these cases, a Markman hearing is scheduled for August 2025, and trial is scheduled for February 2026. Dell, HPI and Oracle filed their answers in June, August and September 2024, respectively. The Markman hearing in those matters was held in May 2025, and trial is scheduled for June 2026. Lenovo filed a motion to dismiss for lack of jurisdiction in July 2024, which was denied, and it subsequently filed an answer in October 2024. HPE and Acer filed their answers in July and September 2024, respectively. The Markman hearing for the Lenovo, HPE and Acer matters is scheduled for September 2025, and trial in those matters is scheduled for March 2026. AWS moved to dismiss the complaint in June 2025, and EireOg responded with an amended complaint. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters.

| Financial Statements | Notes to Financial Statements | 24

Table of Contents

Key Terms |

We use terms throughout our document that are specific to Intel or that are abbreviations that may not be commonly known or used. Below is a list of these terms used in our document.

Term |  | Definition
2024 Restructuring Plan |  | Cost and capital reduction initiatives approved by management, the board of directors or the Audit & Finance Committee of the board of directors designed to adjust spending to current business trends and achieve objectives announced in Q3 2024 with respect to reducing operating expenses, reducing capital expenditures and reducing cost of sales while enabling Intel's new operating model and continuing to fund investments in Intel's core strategy
2025 Restructuring Plan |  | Transformational initiative approved by our management to lower expenses, streamline our organizational structure and reduce management layers across functions while reallocating resources toward our core client and server businesses by reducing investment in lower-priority programs and initiatives
AI |  | Artificial intelligence
Apollo |  | Apollo Global Management, Inc. |  |
ASP |  | Average selling price
Brookfield |  | Brookfield Asset Management |  |
CCG |  | Client Computing Group operating segment
CHIPS Act |  | Creating Helpful Incentives to Produce Semiconductors for America Act
CODM |  | Chief operating decision maker
CPU |  | Processor or central processing unit
DCAI |  | Data Center and Artificial Intelligence operating segment
EC |  | European Commission
EPS |  | Earnings per share |  |
2024 Form 10-K |  | Annual Report on Form 10-K for the year ended December 28, 2024
FPGA |  | Field-programmable gate array
IDM |  | Integrated device manufacturer, a semiconductor company that both designs and builds chips
IMS |  | IMS Nanofabrication GmbH, a business within Intel Foundry that develops and produces electron-beam systems for the semiconductor industry
IP |  | Intellectual property
MD&A |  | Management's Discussion and Analysis
MG&A |  | Marketing, general, and administrative
NAND |  | NAND flash memory
NEX |  | Networking and Edge operating segment
R&D |  | Research and development
RSU |  | Restricted stock unit
SCIP |  | Semiconductor Co-Investment Program |  |
SEC |  | US Securities and Exchange Commission
Smart Capital |  | Our Smart Capital approach accelerates progress on our strategy. This approach is designed to enable us to adjust quickly to opportunities in the market, while managing our margin structure and capital spending. The elements of Smart Capital include capacity investments, government incentives, customer commitments, continued use of external foundries
SoC |  | System on a chip, which integrates most of the components of a computer or other electronic system into a single silicon chip. We offer a range of SoC products in CCG, DCAI, and NEX. Our DCAI and NEX businesses offer SoCs across many market segments for a variety of applications, including products targeted for 5G base stations and network infrastructure
US |  | United States |  |
US GAAP |  | US Generally Accepted Accounting Principles
VIE |  | Variable interest entity

| Financial Statements | Notes to Financial Statements | 25

Table of Contents

Management's Discussion and Analysis |

This report should be read in conjunction with our 2024 Form 10-K where we include additional information on our business, operating segments, risk factors, critical accounting estimates, policies, and the methods and assumptions used in our estimates, among other important information. The Critical Accounting Estimates discussed in this Form 10-Q supplement the significant accounting policies outlined in "Note 2: Accounting Policies" within Notes to Consolidated Financial Statements within our Annual Report on Form 10-K for the fiscal year ended December 28, 2024.
In Q2 2025, we initiated an enterprise-wide initiative to fundamentally transform our culture and the way in which we operate, which is designed to simplify the way we do business and drive transparency and accountability across the company. As part of this transformation, we implemented the 2025 Restructuring Plan to lower expenses, streamline our organizational structure and reduce management layers across functions while reallocating resources toward our core client and server businesses by reducing investment in lower-priority programs and initiatives. We expect these headcount reduction initiatives will reduce our core Intel workforce by 15% by the end of fiscal 2025. As a result of initiating and deploying the 2025 Restructuring Plan, and substantially completing the 2024 Restructuring Plan, we recognized restructuring charges of $1.9 billion in Q2 2025, primarily comprised of the following:
▪cash-based employee severance and related employee exit charges of $1.5 billion; and
▪non-cash asset impairment charges of $416 million resulting from the exit of certain non-core lines of business and the consolidation and exit of certain real estate properties.
Our Q2 2025 results of operations were also affected by an impairment charge and accelerated depreciation related to certain manufacturing assets that were determined to have no remaining operational use. This determination was based on an evaluation of our current process technology node capacities relative to projected market demand for our products and services. These non-cash charges of $797 million, net of certain items, were recorded to cost of sales in Q2 2025, impacting the results for our Intel Foundry segment.
As part of the transformation of the company, we have begun implementing a more disciplined approach to the deployment of capital. The design, development, and manufacturing of leading-edge semiconductor manufacturing process technologies, or nodes, is risky and capital-intensive, and it takes years for capital investments to yield a return. Under our more disciplined approach, we intend to invest capital in future node development and additional or upgraded manufacturing facilities only where we have a clear line of sight to an acceptable return on that capital. We expect to release the first SKU of our first products manufactured on our new leading-edge node, Intel 18A, by the end of 2025, and continue to develop its derivative node, Intel 18A-P, designed for future Intel products and external customers. We are focused on the continued development of Intel 14A, the next generation node beyond Intel 18A and Intel 18A-P, and on securing a significant external customer for such node. However, if we are unable to secure a significant external customer and meet important customer milestones for Intel 14A, we face the prospect that it will not be economical to develop and manufacture Intel 14A and successor leading-edge nodes on a go-forward basis. In such event, we may pause or discontinue our pursuit of Intel 14A and successor nodes and various of our manufacturing expansion projects. While we continue to evaluate Intel 14A for use in future Intel products and our plan includes an initial product designed to utilize Intel 14A, at present we are maintaining the option to design future Intel products requiring nodes with performance beyond Intel 18A and Intel 18A-P to be produced internally or by an external foundry. If we were to discontinue development of Intel 14A and successor nodes, we expect that a majority of our products would continue to be manufactured in our own facilities utilizing our nodes up to Intel 18A-P through at least 2030. By focusing on our customers and delivering the best semiconductor products to the market, manufactured on the most appropriate internal or external node from a performance and cost perspective, and only deploying capital on new nodes and manufacturing facilities where we believe they will yield an attractive return, we believe we can improve the competitiveness of our products business, and the overall financial results for the company.
Separately, in recent months, hostilities in Israel and the surrounding region escalated significantly with direct military actions between Israel and Iran and military strikes by the United States against Iran. There can be no assurance that any existing or future ceasefire agreements will be respected or remain in force, and additional hostilities and escalations remain possible at any time. We continue to monitor the impact this geopolitical conflict could have on our operations in Israel, including potential disruption of our wafer fabrication facility and our product development centers. To date, we have not had a material interruption in either our manufacturing operations or our product development centers. As a significant portion of our revenues are generated from products on Intel 7 manufactured at our fabrication facility in Israel and we are not insured for business interruptions resulting from war or political violence, a disruption of that facility could have a significant adverse impact on our business. Additionally, our property, plant, and equipment assets in Israel are self-insured for losses resulting from war or political violence and could be impacted by the conflict.
In Q1 2025, we made an organizational change to integrate NEX into CCG and DCAI and modified our segment reporting to align to this and certain other business reorganizations. All prior period segment data has been retrospectively adjusted to reflect the way our CODM internally receives information and manages and monitors our operating segment performance. There were no changes to our consolidated financial statements for any prior periods. Our discussion regarding our segments' results of operations presented below excludes the $1.9 billion of restructuring and other charges in Q2 2025 and similar charges for the other periods presented, as our CODM receives, views and uses information for decision making purposes based upon segment results that exclude such items. "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements of this Form 10-Q provides additional information about our operating segments, including the nature of segment revenues and expenses, and reconciles our segment revenues presented below to our total consolidated net revenues and our segment operating income (loss) presented below to our total consolidated operating income (loss) for each of the periods presented.

| MD&A | 26

Table of Contents

Operating Segments Trends and Results |

Intel Products
Intel Products consists substantially of the design, development, marketing, sale, support, and servicing of CPUs and related solutions for third-party customers. The manufacturing of our Intel Products' offerings is performed by Intel Foundry and, to a lesser extent, certain third party manufacturers. Intel Products is comprised of two operating segments: CCG and DCAI. CCG delivers platforms and processors that power personal computers, enabling enhanced performance, connectivity and user experiences. DCAI provides high-performance computing, AI acceleration, and infrastructure solutions, supporting data centers, cloud providers, and enterprises in meeting the growing demand for data processing and AI workloads.
Intel Products Financial Performance 1

|  | Three Months Ended |  | Six Months Ended
|  | Jun 28, 2025 |  | Jun 28, 2025
($ in Millions) |  | CCG |  | DCAI |  | Total |  | CCG |  | DCAI |  | Total
Revenue |  | $ | 7,871 |  |  | $ | 3,939 |  |  | $ | 11,810 |  |  | $ | 15,500 |  |  | $ | 8,065 |  |  | $ | 23,565 |
Cost of sales and operating expenses |  | 5,818 |  |  | 3,306 |  |  | 9,124 |  |  | 11,086 |  |  | 6,857 |  |  | 17,943 |
Operating income |  | $ | 2,053 |  |  | $ | 633 |  |  | $ | 2,686 |  |  | $ | 4,414 |  |  | $ | 1,208 |  |  | $ | 5,622 |
Operating margin % |  | 26 | % |  | 16 | % |  | 23 | % |  | 28 | % |  | 15 | % |  | 24 | %

|  | Three Months Ended |  | Six Months Ended
|  | Jun 29, 2024 |  | Jun 29, 2024
($ in Millions) |  | CCG |  | DCAI |  | Total |  | CCG |  | DCAI |  | Total
Revenue |  | $ | 8,143 |  |  | $ | 3,805 |  |  | $ | 11,948 |  |  | $ | 16,416 |  |  | $ | 7,633 |  |  | $ | 24,049 |
Cost of sales and operating expenses |  | 5,502 |  |  | 3,563 |  |  | 9,065 |  |  | 10,953 |  |  | 6,974 |  |  | 17,927 |
Operating income |  | $ | 2,641 |  |  | $ | 242 |  |  | $ | 2,883 |  |  | $ | 5,463 |  |  | $ | 659 |  |  | $ | 6,122 |
Operating margin % |  | 32% |  | 6% |  | 24% |  | 33% |  | 9% |  | 25%

1 Operating segment results include intersegment financial activity; refer to "Note 2: Operating Segments" for a reconciliation between our operating segment and consolidated financial results for the periods presented.

Operating Segment Revenue Summary

Q2 2025 vs. Q2 2024 |  |  |  |

Total Intel Products revenue was $11.8 billion in Q2 2025, down $138 million from Q2 2024.
▪CCG revenue decreased $272 million from Q2 2024. Client revenue (collectively notebook and desktop) was $6.6 billion in Q2 2025, down $390 million from Q2 2024, primarily due to lower Q2 2025 c lient volume resulting from incremental customer incentives offered to certain customers in Q2 2024. Client ASPs in Q2 2025 were roughly flat with Q2 2024. Other CCG revenue was $1.3 billion, up $118 million from Q2 2024.
▪DCAI revenue increased $134 million from Q2 2024, primarily driven by higher Q2 2025 server revenue due to higher hyperscale customer-related demand which contributed to an increase in server volume of 13% . Server ASPs decreased 8% from Q2 2024, primarily due to pricing actions taken in a competitive environment.

YTD 2025 vs. YTD 2024 |  |  |  |

Total Intel Products revenue was $23.6 billion in YTD 2025, down $484 million from YTD 2024.
▪CCG revenue decreased $916 million from YTD 2024. Client revenue (collectively notebook and desktop) was $13.2 billion in YTD 2025, down $988 million from YTD 2024, primarily due to lower YTD 2025 client volume resulting from incremental customer incentives offered to certain customers in YTD 2024. Client ASPs in YTD 2025 were roughly flat with YTD 2024. Other CCG revenue was $2.3 billion, up $72 million from YTD 2024.
▪DCAI revenue increased $432 million from YTD 2024, primarily driven by higher server revenue due to higher hyperscale customer-related demand which contributed to an increase in server volume of 15%. Server ASPs decreased by 9% from YTD 2024, primarily due to pricing actions taken in a competitive environment. Other DCAI product revenue also increased from YTD 2024 driven by higher edge processing unit demand.

| MD&A | 27

Table of Contents

Segment Operating Income Summary

Q2 2025 vs. Q2 2024 |  |  |  |

Total Intel Products operating income was $2.7 billion in Q2 2025, down $197 million from Q2 2024.
▪CCG operating income decreased $588 million from Q2 2024, primarily due to $831 million of unfavorable impacts attributable to lower product profit due to lower revenue in Q2 2025, and higher period charges related to higher inventory reserves and one-time period costs of $188 million. These decreases to operating income in Q2 2025 were partially offset by the Q2 2025 favorable impacts of lower operating expenses of $243 million, primarily driven by lower payroll-related expenditures resulting from headcount reductions taken under the 2024 Restructuring Plan and the effects of various other cost-reduction measures.
▪DCAI operating income increased $391 million from Q2 2024, primarily due to the favorable impacts of lower operating expenses of $524 million that were primarily driven by lower payroll-related expenditures resulting from headcount reductions taken under the 2024 Restructuring Plan and the effects of various other cost-reduction measures.

YTD 2025 vs. YTD 2024 |  |  |  |

Total Intel Products operating income was $5.6 billion in YTD 2025, down $500 million from YTD 2024.
▪CCG operating income decreased $1.0 billion from YTD 2024, primarily due to $1.5 billion of unfavorable impacts attributable to lower product profit due to lower revenue in YTD 2025, as well as higher period charges related to higher inventory reserves and higher one-time period charges of $188 million. These unfavorable YTD 2025 impacts were partially offset by YTD 2025 favorable impacts of lower operating expenses of $406 million due to lower payroll-related expenditures as a result of headcount reductions taken under the 2024 Restructuring Plan and the effects of various other cost-reduction measures.
▪DCAI operating income increased $549 million from YTD 2024, primarily due to $998 million of favorable impacts related to lower operating expenses, driven by lower payroll-related expenditures as a result of headcount reductions taken under the 2024 Restructuring Plan and the effects of various other cost-reduction measures. These favorable YTD 2025 impacts were partially offset by unfavorable impacts to operating income, primarily due to period charges of $361 million related to Gaudi AI Accelerator inventory-related charges recognized in YTD 2025.
Intel Foundry
Intel Foundry, comprising technology development, manufacturing and foundry services, seeks to deliver the best systems foundry capabilities to support Intel Products and external customers. We are working to innovate and advance world-class silicon process and advanced packaging technologies and to strengthen the resilience of the global semiconductor supply chain by investing in geographically balanced and more sustainable manufacturing capacity.
Intel Foundry Financial Performance 1

|  | Three Months Ended |  | Six Months Ended |  |
($ in Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024 |  |
Revenue |  | $ | 4,417 |  |  | $ | 4,282 |  |  | $ | 9,084 |  |  | $ | 8,638 |  |  |
Cost of sales and operating expenses |  | 7,585 |  |  | 7,084 |  |  | 14,572 |  |  | 13,881 |  |  |
Operating loss |  | $ | (3,168) |  |  | $ | (2,802) |  |  | $ | (5,488) |  |  | $ | (5,243) |  |  |
Operating loss % |  | (72)% |  | (65)% |  | (60)% |  | (61)% |  |

1 Operating segment results include intersegment financial activity; refer to "Note 2: Operating Segments" for a reconciliation between our operating segment and consolidated financial results for the periods presented.

Operating Segment Revenue Summary

Q2 2025 vs. Q2 2024 |  |  |  |

Revenue was $4.4 billion in Q2 2025, up $135 million from Q2 2024. Intersegment revenue was $4.4 billion, up $152 million from Q2 2024, primarily due to higher back-end services revenue and higher expedite fees, partially offset by lower intersegment sample revenue. External revenue was $22 million, down $17 million from Q2 2024.

YTD 2025 vs. YTD 2024 |  |  |  |

Revenue was $9.1 billion in YTD 2025, up $446 million from YTD 2024. Intersegment revenue was $9.0 billion, up $445 million from YTD 2024, primarily due to higher back-end services revenue, higher expedite fees, and higher wafer volume from our Intel 3 and Intel 4 process nodes, partially offset by lower intersegment sample revenue. External revenue was $53 million, roughly flat with YTD 2024.

| MD&A | 28

Table of Contents

Segment Operating Loss Summary

Q2 2025 vs. Q2 2024 |  |  |  |

Operating loss was $3.2 billion in Q2 2025, compared to an operating loss of $2.8 billion in Q2 2024, primarily driven by non-cash asset impairment and accelerated depreciation charges of $797 million recognized in Q2 2025 related to certain manufacturing assets that were determined to have no remaining operational use based on an evaluation of our current process technology node capacities relative to projected market demand for our products and services. This increase in operating loss in Q2 2025 was partially offset by the favorable impacts of higher intersegment revenue and a $185 million benefit from lower operating expenses in Q2 2025, primarily due to lower payroll-related expenditures as a result of headcount reductions taken under the 2024 Restructuring Plan and the effects of various cost-reduction measures.

YTD 2025 vs. YTD 2024 |  |  |  |

Operating loss was $5.5 billion in YTD 2025, compared to an operating loss of $5.2 billion in YTD 2024, primarily driven by non-cash asset impairment and accelerated depreciation charges of $797 million related to certain manufacturing assets that were determined to have no remaining operational use based on an evaluation of our current process technology node capacities relative to projected market demand for our products and services. This increase in operating loss in YTD 2025 was partially offset by the favorable impacts of higher intersegment revenue and a $323 million benefit from lower operating expenses in YTD 2025, primarily due to lower payroll-related expenditures as a result of headcount reductions taken under the 2024 Restructuring Plan and the effects of various cost-reduction measures.
All Other
Our "all other" category includes the results of operations from other non-reportable segments not otherwise presented, including our Altera and Mobileye businesses, our IMS business, start-up businesses that support our initiatives, and historical results of operations from divested businesses. Altera offers programmable semiconductors, primarily FPGAs, and related products, for a broad range of applications across our embedded, communications, cloud, enterprise, and defense and aerospace market segments. On April 14, 2025, we entered into an agreement with SLP VII Gryphon Aggregator, L.P., an affiliate of Silver Lake Partners, to sell 51% of all issued and outstanding common stock of Altera. The transaction is expected to close in the second half of 2025, subject to customary closing conditions and regulatory approvals. Upon closing, we expect to deconsolidate Altera from our financial results as a consolidated subsidiary and begin to account for our minority investment in Altera under the equity method of accounting. Mobileye is a global leader in driving assistance and self-driving solutions, with a product portfolio designed to encompass the entire stack required for assisted and autonomous driving, including compute platforms, computer vision, and machine learning-based perception, mapping and localization, driving policy, and active sensors in development. IMS specializes in developing and manufacturing multi-beam mask writing tools.
All Other Financial Performance 1

|  | Three Months Ended |  | Six Months Ended
($ in Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Revenue |  | $ | 1,053 |  |  | $ | 881 |  |  | $ | 1,996 |  |  | $ | 1,524 |
Cost of sales and operating expenses |  | 984 |  |  | 927 |  |  | 1,824 |  |  | 1,740 |
Operating income (loss) |  | $ | 69 |  |  | $ | (46) |  |  | $ | 172 |  |  | $ | (216) |
Operating margin (loss) % |  | 7 | % |  | (5) | % |  | 9 | % |  | (14) | %

1 Operating segment results include intersegment financial activity; refer to "Note 2: Operating Segments" for a reconciliation between our operating segment and consolidated financial results for the periods presented.

| MD&A | 29

Table of Contents

Operating Segment Revenue Summary

Q2 2025 vs. Q2 2024

All other revenue was $1.1 billion, up $172 million from Q2 2024. Mobileye revenue was $507 million, up $68 million from Q2 2024, primarily driven by higher demand for EyeQ® products. Altera revenue was $448 million, up $87 million from Q2 2024, primarily driven by higher demand for FPGA products.

YTD 2025 vs. YTD 2024

All other revenue was $2.0 billion, up $472 million from YTD 2024. Mobileye revenue was $945 million, up $267 million from YTD 2024 as customer inventory levels improved compared to higher levels in YTD 2024. Altera revenue was $816 million, up $113 million from YTD 2024, primarily driven by higher demand for FPGA products.

Segment Operating Income (Loss) Summary

Q2 2025 vs. Q2 2024

Total all other operating income was $69 million, up $115 million from Q2 2024, primarily driven by higher Mobileye and Altera revenue.

YTD 2025 vs. YTD 2024

Total all other operating income was $172 million, up $388 million from YTD 2024, primarily driven by higher Mobileye and Altera revenue.

| MD&A | 30

Table of Contents

Consolidated Condensed Results of Operations |

|  | Three Months Ended |  | Six Months Ended
|  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
(In Millions, Except Per Share Amounts) |  | Amount |  | % of Net Revenue |  | Amount |  | % of Net Revenue |  | Amount |  | % of Net Revenue |  | Amount |  | % of Net Revenue
Net revenue |  | $ | 12,859 |  |  | 100.0 | % |  | $ | 12,833 |  |  | 100.0 | % |  | $ | 25,526 |  |  | 100.0 | % |  | $ | 25,557 |  |  | 100.0 | %
Cost of sales |  | 9,317 |  |  | 72.5 | % |  | 8,286 |  |  | 64.6 | % |  | 17,312 |  |  | 67.8 | % |  | 15,793 |  |  | 61.8 | %
Gross profit |  | 3,542 |  |  | 27.5 | % |  | 4,547 |  |  | 35.4 | % |  | 8,214 |  |  | 32.2 | % |  | 9,764 |  |  | 38.2 | %
Research and development |  | 3,684 |  |  | 28.6 | % |  | 4,239 |  |  | 33.0 | % |  | 7,324 |  |  | 28.7 | % |  | 8,621 |  |  | 33.7 | %
Marketing, general, and administrative |  | 1,144 |  |  | 8.9 | % |  | 1,329 |  |  | 10.4 | % |  | 2,321 |  |  | 9.1 | % |  | 2,885 |  |  | 11.3 | %
Restructuring and other charges |  | 1,890 |  |  | 14.7 | % |  | 943 |  |  | 7.3 | % |  | 2,046 |  |  | 8.0 | % |  | 1,291 |  |  | 5.1 | %
Operating income (loss) |  | (3,176) |  |  | (24.7) | % |  | (1,964) |  |  | (15.3) | % |  | (3,477) |  |  | (13.6) | % |  | (3,033) |  |  | (11.9) | %
Gains (losses) on equity investments, net |  | 502 |  |  | 3.9 | % |  | (120) |  |  | (0.9) | % |  | 390 |  |  | 1.5 | % |  | 85 |  |  | 0.3 | %
Interest and other, net |  | (95) |  |  | (0.7) | % |  | 80 |  |  | 0.6 | % |  | (268) |  |  | (1.0) | % |  | 225 |  |  | 0.9 | %
Income (loss) before taxes |  | (2,769) |  |  | (21.5) | % |  | (2,004) |  |  | (15.6) | % |  | (3,355) |  |  | (13.1) | % |  | (2,723) |  |  | (10.7) | %
Provision for (benefit from) taxes |  | 255 |  |  | 2.0 | % |  | (350) |  |  | (2.7) | % |  | 556 |  |  | 2.2 | % |  | (632) |  |  | (2.5) | %
Net income (loss) |  | (3,024) |  |  | (23.5) | % |  | (1,654) |  |  | (12.9) | % |  | (3,911) |  |  | (15.3) | % |  | (2,091) |  |  | (8.2) | %
Less: net income (loss) attributable to non-controlling interests |  | (106) |  |  | (0.8) | % |  | (44) |  |  | (0.3) | % |  | (172) |  |  | (0.7) | % |  | (100) |  |  | (0.4) | %
Net income (loss) attributable to Intel |  | $ | (2,918) |  |  | (22.7) | % |  | $ | (1,610) |  |  | (12.5) | % |  | $ | (3,739) |  |  | (14.6) | % |  | $ | (1,991) |  |  | (7.8) | %
Earnings (loss) per share attributable to Intel—diluted |  | $ | (0.67) |  |  |  |  | $ | (0.38) |  |  |  |  | $ | (0.86) |  |  |  |  | $ | (0.47) |  |  |

| MD&A | 31

Table of Contents
Consolidated Revenue

Consolidated Revenue Walk $B 1 |

Q2 2025 vs. Q2 2024

Our Q2 2025 revenue was $12.9 billion, roughly flat with Q2 2024. Intel Products revenue decreased 1% primarily due to lower CCG revenue, partially offset by higher DCAI revenue. CCG revenue decreased 3% from Q2 2024, primarily due to lower client revenue driven by lower Q2 2025 client volumes that were primarily attributable to the reduction of incremental purchasing incentives offered to certain customers in Q2 2024. DCAI revenue increased 4% from Q2 2024, primarily driven by higher server revenue due to higher hyperscale customer-related demand. All other revenue increased 21% from Q2 2024, primarily driven by higher Altera revenue and higher Mobileye revenue.
Incentives offered to certain customers to accelerate purchases and to strategically position our products with customers for market segment share purposes, particularly in CCG, contributed approximately $1.3 billion to our revenue during Q2 2024. These incentives were insignificant in Q2 2025.
YTD 2025 vs. YTD 2024
Our YTD 2025 revenue was $25.5 billion, roughly flat with YTD 2024. Intel Products revenue decreased 2% from YTD 2024 primarily due to lower CCG revenue, partially offset by higher DCAI revenue. CCG revenue decreased 6% from YTD 2024 primarily due to lower client revenue driven by lower YTD 2025 client volumes that were primarily attributable to the reduction of incremental purchasing incentives offered to certain customers in YTD 2024. DCAI revenue increased 6% from YTD 2024 primarily due to higher server revenue due to higher hyperscale customer-related demand and higher product revenue from increased edge processing unit demand. All other revenue increased 31% from YTD 2024, driven by higher Altera revenue and higher Mobileye revenue.
1 Excludes intersegment revenue; totals may not sum due to rounding.

| MD&A | 32

Table of Contents
Consolidated Gross Profit
We derived a majority of our consolidated gross profit in Q2 2025 and in YTD 2025 from our Intel Products business sales through our CCG and DCAI operating segments.

| Gross Profit $B
| (Percentages in chart indicate gross profit as a percentage of total revenue)

Q2 2025 vs. Q2 2024
Our consolidated gross profit in Q2 2025 decreased by $1.0 billion, or 22%, compared to Q2 2024, primarily driven by asset impairment and accelerated depreciation charges related to certain manufacturing assets that were determined to have no remaining operational use. This determination was based on an evaluation of our current process technology node capacities relative to projected market demand for our products and services. These non-cash charges of $797 million were recorded to cost of sales in Q2 2025, impacting the results of our Intel Foundry segment. Consolidated gross profit also decreased in Q2 2025 due to higher one-time period charges of $209 million, and higher period charges related to Gaudi AI accelerator inventory reserves taken in Q2 2025.
YTD 2025 vs. YTD 2024
Our consolidated gross profit in YTD 2025 decreased by $1.6 billion, or 16%, compared to YTD 2024, primarily driven by asset impairment and accelerated depreciation charges related to certain manufacturing assets that were determined to have no remaining operational use. This determination was based on an evaluation of our current process technology node capacities relative to projected market demand for our products and services. These non-cash charges of $797 million were recorded to cost of sales in Q2 2025, impacting the results of our Intel Foundry segment. Consolidated gross profit also decreased in YTD 2025 due to higher period charges of $361 million related to Gaudi AI accelerator inventory reserves taken in YTD 2025 and higher one time period charges of $209 million.

| MD&A | 33

Table of Contents
Consolidated R&D and MG&A Expenses
Total R&D and MG&A expenses for Q2 2025 were $4.8 billion, down 13% from Q2 2024, and $9.6 billion for YTD 2025, down 16% from YTD 2024. These expenses represent 37.5% of revenue for Q2 2025 and 43.4% of revenue for Q2 2024, and 37.8% of revenue for YTD 2025 and 45.0% of revenue for YTD 2024. In support of our strategy, described in our 2024 Form 10-K, we continue to make investments to advance our process technology roadmap. As a result of our 2025 Restructuring Plan, 2024 Restructuring Plan, and related cost-reduction measures, we expect a decrease in total R&D and MG&A expenses in 2025 relative to recent historical periods as we focus investments in R&D and create capacity for sustained investment in technology and manufacturing.

| Research and Development $B |  | Marketing, General, and Administrative $B

(Percentages in chart indicate operating expenses as a percentage of total revenue)

Research and Development

Q2 2025 vs. Q2 2024
R&D decreased by $555 million, or 13%, compared to Q2 2024 primarily driven by lower payroll-related expenditures resulting from headcount reductions taken under the 2024 Restructuring Plan, the effects of various other cost-reduction measures, and lower share-based compensation, partially offset by higher incentive-based cash compensation.
YTD 2025 vs. YTD 2024
R&D decreased by $1.3 billion, or 15%, primarily driven by lower payroll-related expenditures resulting from headcount reductions taken under the 2024 Restructuring Plan, the effects of various other cost-reduction measures, and lower shared-based compensation, partially offset by higher incentive-based cash compensation.

Marketing, General, and Administrative

Q2 2025 vs. Q2 2024
MG&A decreased by $185 million, or 14%, compared to Q2 2024 primarily driven by lower payroll-related expenditures resulting from headcount reductions taken under the 2024 Restructuring Plan, and the effects of various other cost-reduction measures, partially offset by higher incentive-based cash compensation.
YTD 2025 vs. YTD 2024
MG&A decreased by $564 million, or 20%, primarily driven by lower payroll-related expenditures resulting from headcount reductions taken under the 2024 Restructuring Plan, the effects of various other cost-reduction measures, and lower share-based compensation, partially offset by higher incentive-based cash compensation.

| MD&A | 34

Table of Contents
Restructuring and Other Charges

|  | Three Months Ended |  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Employee severance and benefit arrangements |  | $ | 1,466 |  |  | $ | 165 |  |  | $ | 1,607 |  |  | $ | 294 |
Litigation charges and other |  | 8 |  |  | 778 |  |  | 20 |  |  | 778 |
Asset impairment charges |  | 416 |  |  | — |  |  | 419 |  |  | 219 |
Total restructuring and other charges |  | $ | 1,890 |  |  | $ | 943 |  |  | $ | 2,046 |  |  | $ | 1,291 |

In Q2 2025, we announced and commenced the 2025 Restructuring Plan, which is expected to streamline our organizational structure, enabling us to focus on our core businesses and resulting in lower overall operating expenses (see "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements). We expect actions pursuant to the 2025 Restructuring Plan to be substantially complete by Q4 2025, which is subject to change. Any changes to the estimates or timing will be reflected in our results of operations.
The 2024 Restructuring Plan, which we initiated in Q3 2024, was substantially complete in Q2 2025.
Employee severance and benefit arrangements in Q2 2025 includes charges of $1.4 billion relating to the 2025 Restructuring Plan and the remaining charges primarily related to the 2024 Restructuring Plan. In YTD 2025, we incurred charges of $1.4 billion relating to the 2025 Restructuring Plan and $213 million relating to the 2024 Restructuring Plan. Charges of $165 million in Q2 2024 and $294 million in YTD 2024 are primarily related to other restructuring actions taken to streamline operations and to reduce costs.
Litigation charges and other includes a charge of $780 million in Q2 2024 arising out of the R2 litigation. Refer to "Note 19: Commitments and Contingencies" within Notes to Consolidated Financial Statements as included in our Annual Report on Form 10-K for the year ended December 28, 2024 for further information.
Asset impairment charges of $416 million in Q2 2025 primarily include non-cash charges related to the exit of certain non-core lines of business and the consolidation and exit of certain real estate properties in connection with the 2025 Restructuring Plan. In addition, we also incurred a goodwill impairment loss of $222 million in the first six months of 2024 related to our Intel Foundry reporting unit (refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for further information).

| MD&A | 35

Table of Contents
Gains (Losses) on Equity Investments and Interest and Other, Net

|  | Three Months Ended |  | Six Months Ended |  |  |  |  |
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024 |  |  |  |  |
Unrealized gains (losses) on marketable equity investments |  | $ | (58) |  |  | $ | (222) |  |  | $ | (350) |  |  | $ | 30 |  |  |  |  |  |
Unrealized gains (losses) on non-marketable equity investments 1 |  | 473 |  |  | 24 |  |  | 473 |  |  | 48 |  |  |  |  |  |
Impairment charges |  | (51) |  |  | (91) |  |  | (156) |  |  | (159) |  |  |  |  |  |
Unrealized gains (losses) on equity investments, net |  | 364 |  |  | (289) |  |  | (33) |  |  | (81) |  |  |  |  |  |
Realized gains (losses) on sales of equity investments, net |  | 138 |  |  | 169 |  |  | 423 |  |  | 166 |  |  |  |  |  |
Gains (losses) on equity investments, net |  | $ | 502 |  |  | $ | (120) |  |  | $ | 390 |  |  | $ | 85 |  |  |  |  |  |
Interest and other, net |  | $ | (95) |  |  | $ | 80 |  |  | $ | (268) |  |  | $ | 225 |  |  |  |  |  |

1 Unrealized gains (losses) on non-marketable investments includes observable price adjustments and our share of equity method investee gains (losses) and certain distributions.
In Q2 2025, gains (losses) on equity investments, net were primarily driven by unrealized gains (losses) on non-marketable equity investments which included $469 million of upward observable price adjustments, of which $396 million related to a single investee. In YTD 2025, gains (losses) on equity investments, net were driven by upward observable price adjustments and realized gains on sales of equity investments, net, partially offset by unrealized losses on marketable equity investments and impairment charges.
In Q2 2024, gains (losses) on equity investments, net were primarily driven by unrealized losses on our marketable equity investment in Astera Labs, Inc. In YTD 2024, gains (losses) on equity investments, net includes higher realized gains on sales of equity investments, net and a $336 million initial fair value adjustment upon Astera Labs, Inc. shares becoming marketable within unrealized gains (losses) on marketable equity investments, which were partially offset by other mark-to-market losses, as well as impairment charges.
In Q2 2025, interest and other, net decreased to a net expense primarily driven by unfavorable foreign currency movements and a decrease in interest income.
In YTD 2025, interest and other, net decreased to a net expense primarily driven by a $94 million charge related to the sale of our NAND memory business (refer to "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements), unfavorable foreign currency movements, and a decrease in interest income.
Provision for (Benefit from) Taxes

|  | Three Months Ended |  | Six Months Ended
($ In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024 |  | Jun 28, 2025 |  | Jun 29, 2024
Income (loss) before taxes |  | $ | (2,769) |  |  | $ | (2,004) |  |  | $ | (3,355) |  |  | $ | (2,723) |
Provision for (benefit from) taxes |  | $ | 255 |  |  | $ | (350) |  |  | $ | 556 |  |  | $ | (632) |
Effective tax rate |  | (9.2) | % |  | 17.5 | % |  | (16.6) | % |  | 23.2 | %

In Q2 2025 and YTD 2025, our provision for income taxes was determined using our estimated annual effective tax rate, applied to our year-to-date ordinary income (loss) before taxes, adjusted for discrete items. We were also not able to benefit our Q2 2025 and YTD 2025 losses before taxes due to the domestic valuation allowance established in Q3 2024.
In Q2 2024 and YTD 2024, due to our inability to reliably forecast our annual income, our benefit from income taxes was determined using a three and six month actual annual effective tax rate, respectively, adjusted for discrete items.
On July 4, 2025, the One Big Beautiful Bill Act ("the Act") was signed into law. The Act makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, increases the Advanced Manufacturing Investment Credit to 35 percent from 25 percent, and makes modifications to the international tax framework. We are currently evaluating the impact of the Act upon our future effective tax rate, tax liabilities, and cash taxes.

| MD&A | 36

Table of Contents
Liquidity and Capital Resources
We consider the following when assessing our liquidity and capital resources:

(In Millions) |  | Jun 28, 2025 |  | Dec 28, 2024
Cash and cash equivalents |  | $ | 9,643 |  |  | $ | 8,249 |
Short-term investments |  | 11,563 |  |  | 13,813 |
Total cash and short-term investments |  | $ | 21,206 |  |  | $ | 22,062 |
Total debt |  | $ | 50,757 |  |  | $ | 50,011 |

We believe we have sufficient sources of funding to meet our business requirements for the next 12 months and in the longer term. Cash generated by operations, and total cash and short-term investments as shown in the preceding table, are our primary sources of liquidity for funding our strategic business requirements. These sources are further supplemented by our committed credit facilities and other borrowing capacity and certain other Smart Capital initiatives that we have undertaken. Our short-term funding requirements include capital expenditures for worldwide manufacturing and assembly and test, including investments in our process technology roadmap; investments in our product roadmap; working capital requirements including cash outlays associated with the 2025 Restructuring Plan; partner distributions to our non-controlling interest holders; and strategic investments. Our long-term funding requirements incrementally contemplate investments in manufacturing expansion plans and investments to advance our process technology. These plans include expanding existing operations in Arizona, New Mexico, and Oregon, investing in a new leading-edge manufacturing facility in Ohio, and may also include longer-term projects.
In November 2024, we signed a Direct Funding Agreement with the US Department of Commerce for the award of $7.9 billion in government incentives pursuant to the CHIPS Act, from which we have received $2.2 billion of cash to date, $1.1 billion of which was received in Q1 2025. We expect to continue to benefit from government incentives, though recent US government actions create uncertainty as to whether the US government will fulfill its obligation under our CHIPS Act agreements, and support future awards in the US. These government incentives typically require that we make significant capital investments in new facilities or expand existing facilities, and our related workforce, prior to submitting a claim for reimbursement. As of the end of Q2 2025, we have submitted claims for $850 million pursuant to our Direct Funding Agreement for which we have not received reimbursement. To the extent we delay or cancel capital investments or otherwise are unable or fail to comply with the terms of the agreements, there may be a delay in our receipt of, or we may forfeit or be required to repay, the associated government incentives.
In Q1 2025, we closed the second phase of our NAND memory business divestiture and received $1.9 billion of cash proceeds, net of certain adjustments. See "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements for further information.
In Q2 2025, we signed a transaction agreement with SLP VII Gryphon Aggregator, L.P., an affiliate of Silver Lake Partners, to sell 51% of all issued and outstanding common stock of Altera, a wholly owned subsidiary, which is expected to result in receipt of net cash proceeds of $4.4 billion at closing, which is expected to occur in the second half of 2025, with an additional $1.0 billion of the purchase price deferred and payable in two equal $500 million installments no later than December 31, 2026 and December 31, 2027. See "Note 9: Divestitures" within Notes to Consolidated Condensed Financial Statements for further information.
In July 2025, we received net proceeds of $922 million from the net sale of 57.5 million of our Mobileye Class A shares. See "Note 3: Non-Controlling Interests" within Notes to Consolidated Condensed Financial Statements.
Our total cash and short-term investments and related cash flows may be affected by certain discretionary actions we may take with customers and suppliers to accelerate or delay certain cash receipts or payments to manage liquidity, among other factors, for our strategic business requirements. These actions can include, among others, negotiating with suppliers to optimize our payment terms and conditions, adjusting the amounts and timing of cash flows associated with customer sales programs and collections, managing inventory levels and purchasing practices, and selling certain of our accounts receivables on a non-recourse basis to third-party financial institutions. While such actions have benefited, and may further benefit, cash flow in the near term, we may experience a corresponding detriment to cash flow in future periods as these actions cease or as the impacts of these actions reverse or normalize.
In Q1 2025, we amended our 364-day $8.0 billion credit facility agreement to $5.0 billion and the maturity date was extended by one year to January 2026. Additionally, we have access to our $7.0 billion revolving credit facility, which remains available until February 2029. We have other potential sources of liquidity including our commercial paper program and our automatic shelf registration statement on file with the SEC, pursuant to which we may offer an unspecified amount of debt, equity, and other securities. Under our commercial paper program, we have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion. As of June 28, 2025, we had $2.0 billion of commercial paper obligations outstanding and no outstanding borrowings on the revolving credit facilities. See "Note 10: Borrowings" within Notes to Consolidated Condensed Financial Statements for further information. As part of our ongoing capital management strategy to optimize our debt portfolio and reduce interest expense, we may utilize make-whole provisions, tender offers or open market repurchases to repurchase our debt prior to maturity. In YTD 2025 and YTD 2024, we did not extinguish any debt prior to maturity.
We maintain a diverse investment portfolio that we continually analyze based on issuer, industry, and country. Substantially all of our investments in debt instruments were in investment-grade securities.

| MD&A | 37

Table of Contents
Cash flows from operating, investing, and financing activities were as follows:

|  | Six Months Ended
(In Millions) |  | Jun 28, 2025 |  | Jun 29, 2024
Net cash provided by (used for) operating activities |  | $ | 2,863 |  |  | $ | 1,069 |
Net cash provided by (used for) investing activities |  | (2,005) |  |  | (11,728) |
Net cash provided by (used for) financing activities |  | 586 |  |  | 14,867 |
Net increase (decrease) in cash and cash equivalents |  | $ | 1,444 |  |  | $ | 4,208 |

Operating Activities
Operating cash flows consist of net income (loss) adjusted for certain non-cash items and changes in certain assets and liabilities.
Cash provided by operations in the first six months of 2025 was higher compared to the first six months of 2024 primarily due to more favorable changes in working capital. In addition, we incurred higher favorable operating cash flow adjustments for non-cash items that impacted our higher net loss in the first six months of 2025 compared to the first six months of 2024.
Investing Activities
Investing cash flows consist primarily of capital expenditures; investment purchases, sales, maturities, and disposals; proceeds from divestitures; and proceeds from capital-related government incentives.
Cash used for investing activities in the first six months of 2025 was lower compared to the first six months of 2024 primarily due to lower purchases of short-term investments, lower capital expenditures, proceeds from the divestiture of our NAND memory business, and other cash-favorable investing activity in the first six months of 2025. These cash-favorable movements were partially offset by lower maturities and sales of short-term investments in the first six months of 2025 compared to the first six months of 2024.
Financing Activities
Financing cash flows consist primarily of proceeds from strategic initiatives including partner contributions and equity-related issuances, issuance and repayment of short-term and long-term debt, and financing for capital expenditures with extended payment terms.
Cash provided by financing activities in the first six months of 2025 was lower compared to the first six months of 2024 primarily due to lower partner contributions, a net cash decrease in debt-related proceeds, and higher capital expenditures with extended payment terms. These unfavorable cash movements were partially offset by the cash favorable impacts of lower debt-related repayments and no dividend payments in the first six months of 2025 compared to the first six months of 2024.
Critical Accounting Estimates
Our consolidated financial statements are prepared in accordance with US GAAP, which requires us to make certain estimates, judgments and assumptions that can affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Critical accounting estimates are those estimates that involve a significant level of estimation uncertainty and have had, or are reasonably likely to have, a material impact on our financial condition or results of operations. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time such estimates, judgments and assumptions are made. To the extent that there are differences between these estimates, judgments or assumptions and actual results, our financial statements could be affected. We have critical accounting estimates in the areas of inventories, property, plant and equipment, goodwill, and loss contingencies. The discussion provided below supplements the significant accounting policies disclosures provided within "Note 2: Accounting Policies" of Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 28, 2024.
▪ Inventories— inventory is valued at the lower of cost or net realizable value and includes assumptions about future demand and market conditions. The valuation of inventory requires us to estimate obsolete and excess inventory, as well as inventory that is not of saleable quality. We use a demand forecast to develop our short-term manufacturing plans to enable consistency between inventory valuations and build decisions. Significant assumptions and estimates, which evolve each forecast cycle, that are utilized in our demand forecast and obsolete and excess inventory reserves process include:
•customer and product-related factors, including a review of our customer base, the stage of the product life cycle, including limitations to demand forecasting for new products with minimal historical data, variations in market pricing, and an assessment of selling price in relation to product cost;
•market and economic factors, including cyclical changes in market conditions, the introduction of new or alternative products in the marketplace, and the associated pricing environment; and
•other factors, including tariff and export controls.

| MD&A | 38

Table of Contents
Each reporting period, we compare our demand forecast estimate to work-in-process and finished goods inventory levels to determine the amount, if any, of obsolete or excess inventory, which would be reflected in cost of sales and result in a negative impact to our gross profit in that period. If our assumptions and estimates for our demand forecast materially fluctuate and we fail to adjust manufacturing output accordingly or such assumptions and estimates are materially inaccurate, the related obsolete and excess inventory reserves can be materially impacted and result in reduced inventory values for products that we estimate have substantial sales risk. Our estimates for obsolete and excess inventory reserves were materially consistent with actual results in the first half of 2025, in 2024 and in 2023; however, our assumptions and estimates are inherently uncertain, and our gross profit would be adversely affected if future demand is less favorable than forecasted.
▪ Property, plant and equipment—at least annually, we evaluate the period over which we expect to recover the economic value of our property, plant, and equipment, considering factors such as the process technology cadence between node transitions, changes in machinery and equipment technology, and re-use of machinery and tools across each generation of process technology. As we make manufacturing process conversions and other factory planning decisions, we use assumptions involving the use of management judgments regarding the remaining useful lives of assets, primarily process-specific semiconductor manufacturing tools and building improvements. When we determine that the useful lives of assets are shorter or longer than we had originally estimated, we adjust the rate of depreciation to reflect the assets' revised useful lives. In the second quarter of 2025 and in 2024, we evaluated our current process technology node capacities relative to projected market demand for our products and services, and concluded that our manufacturing asset portfolio exceeded manufacturing capacity requirements, which resulted in us shortening the useful lives of certain placed-in-service equipment and recording accelerated depreciation charges of $337 million and $992 million, respectively. In 2023, we determined that the estimated useful lives of certain production-related machinery and equipment should be increased from 5 to 8 years and, when compared to the estimated useful life in place as of the end of 2022, we estimated this change increased gross profit in 2023 by approximately $2.5 billion and decreased R&D expense by approximately $400 million and decreased ending inventory values by approximately $1.3 billion.
Our property, plant and equipment are subject to periodic impairment reviews. Factors that we consider in deciding when to perform an impairment review include significant changes or planned changes in our use and fungibility of certain property, plant and equipment, significant under-performance of a business or product line in relation to expectations for which property, plant and equipment relate, and significant negative industry or economic trends. To perform an impairment review, our property, plant and equipment are grouped and evaluated for impairment at the lowest level of identifiable cash flows, which requires management judgment to form asset groupings and to estimate expected cash flows that are attributable to asset groupings, among other factors. If an indicator of impairment is identified at the asset grouping level, we measure the recoverability of the assets by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows arising from the use of that asset grouping. If an asset grouping carrying value is not determined to be recoverable through this undiscounted cash flows analysis, the asset grouping is considered to be impaired. The resulting charge is classified to expense, which is typically to cost of sales in a similar manner as the corresponding depreciation expense and results in a negative impact to our gross profit in that period. In the second quarter of 2025 and in 2024, we determined certain property and equipment, which had not yet been placed in service, exceeded our projected capacity requirements and incurred non-cash charges of $460 million and $2.3 billion, respectively.
▪ Goodwill—We perform an annual impairment assessment of goodwill at the reporting unit level in the fourth quarter of each year, or more frequently if indicators of potential impairment exist. We have eight reporting units with allocated goodwill, which generally align to our operating segments. We reevaluate our identified reporting units annually or when triggered, such as upon reorganization of our operating segments or due to business reasons that result in material changes as to how our reporting units are organized and managed. Impairment assessments may be qualitative or quantitative in nature. A quantitative assessment is required if we determine, based on a qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying value, or if there are material changes to the structure of our reporting units. The reporting unit's carrying value used in an impairment assessment represents the allocation of various assets and liabilities, excluding certain corporate assets and liabilities, such as cash, investments, and debt. While a substantial majority of our allocable assets, primarily property, plant and equipment, are attributable to our Intel Foundry reporting unit, that reporting unit has no remaining allocated goodwill.
Our qualitative assessment considers industry and market considerations, overall financial performance, and other relevant events and factors affecting our reporting units or Intel as a whole. More specifically, qualitative factors may include a sustained decrease in our consolidated market capitalization or one of our reporting units’ market capitalization relative to each’s respective net book value; significant company specific actions, including changes to the structure of our reporting units; and current, historical or projected deterioration of our financial performance. We may also perform a quantitative analysis to support the qualitative factors by applying sensitivities to assumptions and inputs used in measuring a reporting unit's fair value.
Our quantitative impairment assessment considers both the income approach and the market approach to estimate a reporting unit's fair value. The income approach estimates fair value using discounted future cash flows for a reporting unit primarily using the following major assumptions and inputs: revenue, based on assumed market segment growth rates and our assumed market segment share; estimated costs; and appropriate discount rates based on a reporting unit's weighted average cost of capital. Our quantitative impairment assessment is sensitive to changes in underlying estimates and assumptions, the most sensitive of which is the discount rate. The major inputs and assumptions used in estimating discounted cash flows are derived from historical data, various internal estimates, and a variety of external sources, which are similar to those used in our business planning and forecasting processes. We test the reasonableness of the inputs and outcomes of our discounted cash flow analysis against available market data. Our estimates and assumptions are inherently uncertain and change over time based on operating results, market conditions, and other factors and could materially affect the determination of the fair value and potential goodwill impairment for each reporting unit.

| MD&A | 39

Table of Contents
The market approach estimates fair value using financial multiples and transaction prices of comparable companies.
To corroborate our fair value conclusions, we combine the estimated fair values for all reporting units and perform a market capitalization reconciliation as of the goodwill assessment date to validate the reasonableness of the implied control premium.
In the fourth quarter of 2024, as a part of our annual goodwill impairment assessment, we determined that the estimated fair value of each reporting unit substantially exceeded the assigned carrying value, with the exception of one reporting unit with a significant amount of assigned goodwill: Mobileye. In the third quarter of 2024, we recognized a non-cash goodwill impairment charge of $2.8 billion, substantially all of which related to our Mobileye reporting unit, as the estimated fair value of the reporting unit was lower than the assigned carrying value. As of June 28, 2025, our Mobileye reporting unit had $8.2 billion in recorded goodwill. Mobileye’s market capitalization has increased substantially since the third quarter of 2024 and, while no additional impairment was recognized within the first half of 2025, we continue to closely monitor the Mobileye reporting unit’s financial performance, business forecasts, and market capitalization. As of June 28, 2025, the estimated fair value of the Mobileye reporting unit substantially exceeded the carrying value. Should our estimates change based on Mobileye’s operating results, market conditions, or other factors in our forecast, including changes in the discount rate, the Mobileye reporting unit may become subject to further impairment in future periods. For example, a 1% increase in the discount rate would have resulted in an additional impairment of our Mobileye reporting unit’s goodwill of approximately $1.5 billion in the third quarter of 2024.
▪ Loss contingencies—we are subject to loss contingencies, including various legal and regulatory proceedings, asserted and potential claims, liabilities related to repair or replacement of parts in connection with product defects, as well as product warranties that arise in the ordinary course of business and are subject to change, including due to sudden or rapid developments in proceedings or claims. An estimated loss from such contingencies is recognized as a charge to income if it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. We evaluate developments that could affect prior disclosures or previously accrued liabilities, and make adjustments as appropriate. Significant judgment is required to determine both the likelihood of there being, and the estimated amount of, a loss related to such matters. Certain factors have resulted in significant changes to our judgments and estimates that we made regarding these matters in previous quarters based on updated information that became available. If one or more of these matters were resolved against us for amounts in excess of management's estimates of losses, our results of operations and financial condition could be materially adversely affected.

| MD&A | 40

Table of Contents

Risk Factors and Other Key Information |

Risk Factors
The risks described in "Risk Factors" within Risk Factors and Other Key Information in our 2024 Form 10-K and in our Q1 2025 Form 10-Q could materially and adversely affect our business, financial condition, and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face—our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. In addition to the other information set forth in this Form 10-Q, including in the Forward-Looking Statements, MD&A, and the Consolidated Condensed Financial Statements and Supplemental Details sections, we have provided an additional risk factor below regarding uncertainties surrounding our pursuit of next generation leading-edge process technologies and the impact they could have on our financial results.
If we are unable to secure a significant external foundry customer for Intel 14A, our next generation semiconductor manufacturing process technology, we may pause or discontinue our pursuit of next generation leading-edge process technologies, which may have significant strategic business, financial, operational and reputational risks and repercussions.
As an integrated design manufacturer (IDM) with a products business that depends on access to leading-edge semiconductor manufacturing process technologies, or nodes, to produce competitive products, we have historically invested significant capital resources to continually develop new generations of leading-edge nodes and foundry capacity to produce such nodes. However, the design, development, and manufacturing of leading-edge nodes is risky and capital-intensive, and it takes years for capital investments to yield a return. If we are unable to secure a significant external customer for our Intel 14A node, we may pause or discontinue development of Intel 14A and subsequent next generation leading-edge nodes. While we remain focused on continued development of Intel 14A and securing such a significant external customer, we have taken steps to reduce our overall investment and have further slowed down the construction of the new leading-edge fabrication facilities we are building in Ohio. In addition, while we continue to evaluate Intel 14A for use in future Intel products and our plan includes an initial product designed to utilize Intel 14A, at present we are maintaining the option to design future Intel products requiring nodes with performance beyond Intel 18A and Intel 18A-P to be produced internally or by an external foundry. We have been unsuccessful to date in securing any significant external foundry customers for any of our nodes and our prospects for securing a significant external foundry customer for Intel 14A are uncertain.
If we were to pause or discontinue the design, development, and manufacturing of Intel 14A and other next generation leading-edge nodes, we would be subject to a number of significant strategic business, financial, operational and reputational risks and repercussions including, but not limited to:
▪Dependence on Third-Party Foundries: Our products business would, over time, become dependent on third-party foundries, particularly TSMC, as we develop products for nodes beyond Intel 18A and Intel 18A-P. We have no long-term contract with TSMC, and if we are unable to secure and maintain sufficient capacity on favorable pricing terms, we may be unable to manufacture our products in sufficient volume and at a cost that supports the continued success of our products business. Further, most of our competitors have longer and more established relationships with TSMC and other third-party foundries than we do, which may put us at a competitive disadvantage. There are few foundries capable of producing the leading-edge and near-leading-edge nodes needed for our products – currently only TSMC and Samsung. To the extent our competitors are more successful than us in securing capacity with those foundries than we are, our product roadmap, market position, and customer relationships would be materially adversely impacted.
▪Losses with respect to our Investments in R&D and Manufacturing Facilities and Equipment: We had over $100 billion of property, plant, and equipment, net on our balance sheet as of June 28, 2025, the substantial majority of which we estimate relate to our foundry business. While the significant majority of this relates to our existing and in-development nodes, including Intel 18A and Intel 18A-P, with each transition to a new node we continue to utilize some R&D and manufacturing assets from prior nodes. If we were to pause or discontinue the design, development, and manufacturing of Intel 14A and other next generation leading-edge nodes, we would expect to incur significant material impairments with respect to foundry assets that may impact our results of operations. For example, we would likely discontinue the new leading-edge fabrication facilities we are building in Ohio. We also would expect to incur additional costs and expenses as we wind down other projects and facilities and reduce headcount.
▪Loss of Eligibility for Government Incentives: In November 2024, we signed a Direct Funding Agreement with the US Department of Commerce for the award of $7.9 billion in government incentives. We have also entered into other government incentive arrangements with local, regional, and national governments, both US and non-US. If we were to pause or discontinue the design, development, and manufacturing of Intel 14A, we may lose eligibility for various incentives contemplated by these arrangements, and we may be required to repay amounts already received under these arrangements.
▪Potential Penalty Payments Under our SCIP Agreements: To support our capital investments in recent years, we pursued alternative financing arrangements including our 2022 joint investment with Brookfield in the manufacturing expansion of our Arizona campus and our 2024 joint investment with Apollo related to Fab 34 in Ireland. Our potential pause or discontinuation of the design, development, and manufacture of Intel 14A may accelerate our move to third-party foundry services for our products and result in our inability to satisfy construction and/or wafer demand and purchase commitments in those arrangements, potentially requiring substantial additional payments to our SCIP partners.

| Other Key Information | 41

Table of Contents
▪Loss of Talent: Historically, as one of the only companies in the world, and the only company in the U.S., pursuing the design, development and manufacturing of next generation leading-edge nodes, we have benefitted from being in a unique position as an employer to hire and retain scientists, engineers, and other technical talent interested in being on the cutting edge of semiconductor innovation. If we were to pause or discontinue leading-edge node design, development, and manufacturing, or any perception that we may do so in the future, may materially adversely impact our ability to hire and retain key talent across our foundry organization and the company more broadly, and we risk substantial loss of historical, technical, and other expertise.
▪Limited External Foundry Potential: We have been unsuccessful to date in attracting significant customers to our external foundry business. If we were to pause or discontinue our pursuit of Intel 14A and successor nodes, it is highly uncertain whether we would be able to develop this business. Among other things, our existing nodes (Intel 7, Intel 4 and Intel 3) were designed for Intel products, and if potential customers for our upcoming Intel 18A-P node believe we are no longer committed to continued development of next generation leading-edge nodes (Intel 14A and beyond), they may be inclined to remain with their current foundry partners and unwilling to make the significant investments of time and resources needed to develop products on our nodes.
▪Other Significant Financial, Operational, and Reputational Risks: If we pause or discontinue the design, development and manufacture of Intel 14A and future leading-edge nodes, it may give rise to additional material risks that we are not able to foresee or that are more significant than we anticipate, including, but not limited to, adverse impacts to our relationships and the terms of our engagements with customers, suppliers, and strategic partners, potential credit rating risk, and diminished investor confidence and increased stock price volatility. It is also uncertain what actions, if any, may be taken by the U.S. and other governments to the extent they view a potential discontinuation of our leading-edge process technology design, development, and manufacturing as a strategic risk from a national economic or defense perspective.
Any of the foregoing could have a material adverse impact on our revenue, operations, financial position, cash flows, access to financing, cost structure, competitiveness, reputation, profitability, and prospects and could exacerbate other risks discussed in our 2024 Form 10-K and Q1 2025 Form 10-Q. Further, given the decades of significant continuous investments in R&D, talent accumulation, intellectual property, state-of-the-art facilities, and technical know-how needed to compete in leading-edge node design, development and manufacturing, any decision to pause or discontinue our pursuit of Intel 14A and successor leading-edge process technologies may be effectively irreversible.
Quantitative and Qualitative Disclosures About Market Risk
We are affected by changes in currency exchange and interest rates, as well as equity and commodity prices. Our risk management programs are designed to reduce, but may not entirely eliminate, the impacts of these risks. We performed an evaluation of these risks to our financial positions as of December 28, 2024, and updated that analysis as of June 28, 2025, to determine whether material changes in market risks pertaining to currency and interest rates or equity and commodity prices have occurred as a result of the changes in international trade policies, including tariffs and export controls. No material revisions were noted since disclosing "Quantitative and Qualitative Disclosures About Market Risk" within MD&A, in our 2024 Form 10-K. Risks related to changes in international trade policies, including tariffs and export controls, particularly those involving the United States and China are described under "Risk Factors" within Risk Factors and Other Key Information in our 2024 Form 10-K and in our Q1 2025 Form 10-Q.
Controls and Procedures
Inherent Limitations on Effectiveness of Controls
Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.
Evaluation of Disclosure Controls and Procedures
Based on management’s evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 28, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

| Other Key Information | 42

Table of Contents
Issuer Purchases of Equity Securities
We have an ongoing authorization, originally approved by our Board of Directors in 2005 and subsequently amended, to repurchase shares of our common stock in open market or negotiated transactions. No shares were repurchased during the quarter ending June 28, 2025. As of June 28, 2025, we were authorized to repurchase up to $110.0 billion, of which $7.2 billion remained available.
We issue RSUs as part of our equity incentive plans. In our Consolidated Condensed Financial Statements, we treat shares of common stock withheld for tax purposes on behalf of our employees in connection with the vesting of RSUs as common stock repurchases because they reduce the number of shares that would have been issued upon vesting. These withheld shares of common stock are not considered common stock repurchases under our authorized common stock repurchase program.
Rule 10b5-1 Trading Arrangements
Our directors and officers (as defined in Rule 16a-1 under the Exchange Act) may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the quarter ended June 28, 2025, no such plans or arrangements were adopted or terminated, including by modification.
Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934
Section 13(r) of the Exchange Act requires an issuer to disclose certain information in its periodic reports if it or any of its affiliates knowingly engaged in certain activities, transactions, or dealings with individuals or entities subject to specific US economic sanctions during the reporting period, even when the activities, transactions, or dealings are conducted in compliance with applicable law. On March 2, 2021, the US Secretary of State designated the Federal Security Service of the Russian Federation (FSB) as a party subject to one such sanction. Though Intel has suspended sales in Russia, there may be a need to file documents or engage with FSB as Intel winds up our local Russian offices. All such dealings are explicitly authorized by General License 1B issued by the US Department of the Treasury’s Office of Foreign Assets Control (OFAC), and there are no gross revenues or net profits directly associated with any such dealings by us with the FSB.
On April 15, 2021, the US Department of the Treasury designated Pozitiv Teknolodzhiz, AO (Positive Technologies), a Russian IT security firm, as a party subject to one of the sanctions specified in Section 13(r). Prior to the designation, we communicated with Positive Technologies regarding its IT security research and coordinated disclosure of security vulnerabilities identified by the firm. Based on a license issued by OFAC, we resumed such communications. There are no gross revenues or net profits directly associated with any such activities. We plan to continue these communications in accordance with the terms and conditions of the OFAC license.
Amendment and Restatement of 2006 Equity Incentive Plan
As previously disclosed in our Form 8-K dated May 9, 2025, the Company's stockholders approved an amendment and restatement of the Company's 2006 Equity Incentive Plan (the “EIP”) at the 2025 Annual Stockholders’ Meeting held on May 6, 2025 (the “Annual Meeting”). The amended and restated EIP became effective upon stockholder approval and, among other changes, extended the term of the plan for an additional one year and increased by 150 million the number of shares available under the EIP, as described under Proposal 4 of the Company's definitive proxy statement filed on Schedule 14A with the Securities and Exchange Commission on March 27, 2025.

| Other Key Information | 43

Table of Contents
Exhibits

|  |  |  | Incorporated by Reference |  |
Exhibit Number |  | Exhibit Description |  | Form |  | File Number |  | Exhibit |  | Filing Date |  | Filed or Furnished Herewith
3.1 |  | Corrected Third Restated Certificate of Incorporation of Intel Corporation, dated October 23, 2023 |  | 10-Q |  | 000-06217 |  | 3.1 |  | 10/27/2023 |  |
3.2 |  | Intel Corporation Bylaws, as amended and restated on November 29, 2023 |  | 8-K |  | 000-06217 |  | 3.2 |  | 12/5/2023 |  |
10.1 |  | Transaction Agreement, dated April 14, 2025, by and among Intel Corporation, Intel Americas, Inc., Altera Corporation, and S LP VII Gr yphon Aggregator, L.P. |  |  |  |  |  |  |  |  |  | X
10.2 |  | Form of Limited Partnership Agreement to be entered into by and among Intel Corporation, Intel Americas, Inc., Altera Corporation, and SLP VII Gryphon Aggregator, L.P. |  |  |  |  |  |  |  |  |  | X
10.3† |  | I ntel Corporation 2006 Equity Incentive Plan as Am ended and Restated Effective May 6, 2025 |  |  |  |  |  |  |  |  |  | X
31.1 |  | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act |  |  |  |  |  |  |  |  |  | X
31.2 |  | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act |  |  |  |  |  |  |  |  |  | X
32.1 |  | Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350 |  |  |  |  |  |  |  |  |  | X
101 |  | Inline XBRL Document Set for the consolidated condensed financial statements and accompanying notes in Consolidated Condensed Financial Statements and Supplemental Details |  |  |  |  |  |  |  |  |  | X
104 |  | Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101 |  |  |  |  |  |  |  |  |  | X

† Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.

| Other Key Information | 44

Table of Contents
Form 10-Q Cross-Reference Index

Item Number | Item |
Part I - Financial Information |
Item 1. | Financial Statements | Pages 3 - 24
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations |
| Liquidity and capital resources | Pages 37 - 40
| Results of operations | Pages 26 - 36
| Critical accounting estimates | Page 26, 38
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | Page 42
Item 4. | Controls and Procedures | Page 42
Part II - Other Information |
Item 1. | Legal Proceedings | Pages 21 - 24
Item 1A. | Risk Factors | Page 41
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | Page 43
Item 3. | Defaults Upon Senior Securities | Not applicable
Item 4. | Mine Safety Disclosures | Not applicable
Item 5. | Other Information |
| Rule 10b5-1 Trading Arrangements | Page 43
| Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934 | Page 43
| Amendment and Restatement of 2006 Equity Incentive Plan | Page 43
Item 6. | Exhibits | Page 44
Signatures | Page 46

| Other Key Information | 45

Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  | INTEL CORPORATION (Registrant)
Date: | July 24, 2025 |  | By: |  | /s/ DAVID ZINSNER
|  |  |  |  | David Zinsner
|  |  |  |  | Executive Vice President, Chief Financial Officer, and Principal Financial Officer
Date: | July 24, 2025 |  | By: |  | /s/ SCOTT GAWEL
|  |  |  |  | Scott Gawel
|  |  |  |  | Corporate Vice President, Chief Accounting Officer, and Principal Accounting Officer

|  | 46